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X I V 
Abstract of thesis entitled: 
The role and mechanism of the pro-inflammatory cytokine IL-1 beta on 
megakaryocytopoiesis: the expression of IL-1 receptors and signal 
transduction pathway. 
Submitted by Chuen Ka Yee for the degree of Master of Philosophy at 
The Chinese University of Hong Kong in June 2001. 
Interleukin-lb eta (IL-ip), a highly pro -inflammatory cytokine played a central role 
in the immune and inflammatory responses. IL-lp enhanced early hematopoiesis but 
its effects on the megakaryocytic (MK) lineage have not been confirmed. Our study 
investigated (1) the effects of IL-1 (3 on the growth and development of MK 
progenitors (2) the expressions of IL-1 receptors (IL-IRI and IL-IRII) in human MK 
cell lines and primary cells (3) the effects of IL-1 p on the expressions of c-Jun, c-Fos, 
GATA-1 and NF-E2 in human MK cell lines CHRP and Meg-01 and (4) the 
mechanism of activation by IL-1 (3 in human MK cell line CHRF-288-11 (CHRF), 
including effects of IL-1 receptor antagonist (IL-lRA), human TPO neutralizing 
antibody (TPO Ab), actinomycin D (ActD) and cycloheximide (CHX). 
Our results demonstrated that IL-lp promoted colony-forming unit-megakaryocyte 
(CFU-MK) formation from stem and progenitor cells of murine bone marrow and 
human cord blood. Using semi-quantitative reverse transcription-polymerase chain 
reaction (RT-PCR), Southern blot analysis, flow cytometry and immunofluorescence 
staining, we demonstrated the expressions of IL-IRI and RII on megakaryoblastic 
cell lines CHRF, Meg-01, Dami and M-07e (low expression), as well as primary MK 
cells derived from cord blood and human bone marrow. Upon stimulation by IL-ip 
XIV 
at 25 ng/ml, we demonstrated the upregulation of mRNA expressions of c-Jun (2.9 
fold, peaked at 15 min), c-Fos (3.9 fold, 15 min), GATA-1 (2.4 fold, 60 min) and 
NF-E2 (5.1 fold, 120 min) in CHRF cells. The stimulation was confirmed at the 
protein levels by Western blot analysis which demonstrated an increase of c-Jun (3 
fold，30 min), c-Fos (1.7 fold, 30 min), GATA-1 (11.5 fold, 60 min) and NF-E2 (12.5 
fold, 120 min) in CHRF cells. The elevation of these transcription factors in response 
to IL-ip was consistent in the total cell and nuclear extract and was significantly 
reduced by the pretreatment with ActD (mRNA synthesis inhibitor) or CHX (protein 
synthesis inhibitor), indicating that the mechanism required de novo transcription and 
protein synthesis. 
The direct role of IL-lp in regulating megakaryocytopoiesis was confirmed by the 
addition of IL-IRA, which inhibited the enhancing effects of IL-ip on the mRNA 
and protein expressions of these transcription factors by up to 77%. To investigate 
the possible indirect effects of IL-lp-induced TPO synthesis on the activation of 
these transcription factors, we studied their mRNA and protein expressions in the 
presence of a TPO Ab. No significant diminution of the IL-ip activity was observed. 
In summary, our study demonstrated for the first time that MK cells expressed IL-1 
receptors and that IL-lp might be an effective cytokine in the regulation of 
megakaryocytopoiesis. The action might be mediated by the binding to its receptor 
and the synthesis of the transcription factors c-Jun, c-Fos, GATA-1 and NF-E2. The 
direct involvement of IL-1 (3 in the MK lineage may provide an explanation for the 
phenomenon of thrombocytosis during inflammatory responses. 
xvi 




INDEX FOR FIGURES ix-xii 
INDEX FOR TABLES xiii 
ABSTRACT (Chinese and English) xiv-xvi 
TABLE OF CONTENT xvii 
1. INTRODUCTION 1-37 
2. OBJECTIVES 38-40 
3. METHODS AND MATERIALS 41 70 
4. RESULTS AND DISCUSSION 71-130 






1.1 Interleukin-ip and its receptors 
1.1.1 Interleukin-1 (IL-1) 
1.1.1.1 Structural information 
1.1.1.2 Hematopoietic effects of IL-1 
1.1.2 IL-1 receptor 
1.1.2.1 IL-1 receptor I (IL-IRI) 
1.1.2.2 IL-1 receptor II (IL-IRII) 
1.1.2.3 IL-1 receptor accessory protein (IL-1 RAcP) 
1.1.3 IL-1 receptor antagonist (IL-1RA) 
1.1.4 IL-1 p and inflammation 
1.2 Megakaryocytopoiesis 






1.2.2 Megakaryocytopoiesis and IL-1 (3 
1.2.3 Megakaryocytopoiesis and inflammation 
1 
INTRODUCTION 




1.4 IL-lp signaling 
1.4.1 Activating Protein-1 (AP-1) 
1.4.1.1 Structure and function of c-Jun and c-Fos 
1.4.1.1.1 DNA-binding domain 
1.4.1.1.2 Dimerization 
1.4.1.1.3 DNA-binding 
1.4.1.1.4 Regulation and function of c-Jun 
1.4.1.1.5 Regulation and function of c-Fos 
1.4.1.2 AP-1 in IL-lp signaling 
Figure 1.1 - Figure 1.4 





1.1 Interleukin-lp and its receptors 
1.1.1 Interleukin-1 (IL-1) 
IL-1 was initially described as a polypeptide product of activated macrophages (Gery 
et al, 1972). It was also termed as lymphocyte activating factor, B-cell activating 
factor, leukocyte endogenous mediator, endogenous pyrogene, mononuclear cell 
factor, epidermal cell derived thymocyte activating factor and osteoclast activating 
factor (Dinarello, 1993). The molecular cloning of IL-1 cDNA established the 
presence of two non-allelic genes coding for IL-1 a and IL-1 p. Despite the limited 
similarity in 25% of their sequences, the two proteins bound to the same receptor 
(Kilian et al, 1986; Dower et al, 1986) and demonstrated very similar biological 
activities. Cells that were known to express IL-1 a included astrocytes (Da Cunha et 
al, 1993), fibroblasts (Fini et al, 1994), hepatocytes (Tsukui et al, 1994), 
keratinocytes (Yu et al, 1996), type II Greater alveolar cells (Kumar et al, 1996), 
brown fat adipocytes (Burysek and Houstek, 1996), thymic myeloid cells (Iwakami 
et al, 1996), T cells, eosinophils, dendritic cells (Ghanekar et al, 1996), macrophages 
(Brody and Durum, 1989), monocytes (Mallardo et al, 1994) and oligodendrocytes 
(Da Cunha et al, 1993). Cells that were known to express IL-ip included astrocytes 
(Da Cunha et al, 1993), adrenal cortical cells (Gonzalez-Hernandez et al, 1995), 
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natural killer cells (Jokhi et al, 1997), macrophages, monocytes (Wewers et al, 1997), 
endothelial cells (Warner et al, 1987), keratinocytes (Lundqvist and Egelrud, 1997), 
megakaryocytes (MK) and platelets (Jiang et al, 1994; Loppnow et al, 1998), 
neurons (Freidin et al, 1992), neutrophils (Malyak et al, 1994), oligodendroglia (Da 
Cunha et al, 1993), osteoblasts (Dodds et al, 1994), Schwann cells (Skundric et al, 
1997), trophoblasts (Jokhi et al, 1997), T cells, and fibroblasts (Sporri et al, 1996). 
1.1.1.1 Structural information 
IL-ip precursor consisted of 269 amino acids, cleaved into a 116 amino acid pro-
segment and a 153 amino acid (17 kDa) mature segment (March et al, 1985; 
Thomberry et al, 1992). The IL-lp cleavage was suggested to occur through the 
action of a 45 kDa cysteine protease, IL-lp-converting enzyme (Thomberry et al, 
1992), which was cell-surface associated and under the control of cell membrane 
inhibitors (Hamad et al, 1997; Schonbeck et al, 1997), As IL-ip lacked a secretory 
signal peptide, Hamon et al (1997) proposed that the secretion of the mature and 
fully-active form of IL-lp required the ATP binding cassette transporter. 
IL-la was synthesized as a 271 amino acid (33 kDa) pro-cytokine that was 
enzymatically cleaved by calpain into a bio active 159 amino acid mature segment 
(17 kDa) and a 112 amino acid pro-segment (March et al, 1985; Freidin et al, 1992; 
Watanabe & Kobayashi, 1994). Unlike IL-ip, pro-IL-la was fully active and 
remained intracellular (Mosley et al, 1987). The pro-IL-la could bind to the IL-1 
receptor and hence exerted biological activities without proteolytic processing. IL-la 
also lacked a signal peptide for secretion. Therefore, human mononuclear cells did 
not process or readily secrete mature IL-la even under stimulation by 
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lipopolysaccharide (Lonnemann et al, 1989). 
1.1.1.2 Hematopoietic effects of IL-1 
IL-1 affected hematopoiesis at various levels (Table 1.1) (Bagby, 1989; Fibbe et al, 
1989; Dinarello, 1993; 1996). IL-1 induced the production of granuolocyte 
macrophage-colony stimulating factor (GM-CSF), granuolocyte-colony stimulating 
factor (G-CSF), macrophage-colony stimulating factor (M-CSF), interleukin-3 (IL-)3, 
IL-1, IL-2, IL-6 and IL-8 (Dinarello, 1996). Those cytokines were produced from a 
number of accessory cells such as fibroblasts, endothelial cells, blood marrow 
stromal cells and mononuclear phagocytes (Zsebo et al, 1988; Zucali et al, 1986; 
Bagby et al, 1986), thereby augmenting the differentiation and proliferation of 
hematopoietic progenitor cells (Hangoc et al, 1989; Griffin et al, 1987). Increased 
production of these cytokines could be through new mRNA transcription or, as in the 
case of GM-CSF, through stabilization of mRNA (Griffin et al, 1990; Bagby, 1989). 
IL-1 stimulated hematopoiesis by up-regulating receptors of G-CSF, M-CSF, and 
GM-CSF and induced the proliferation of pluripotent progenitors in the bone marrow 
(Henney, 1988). 
Following a single injection of IL-1 into animals, there were increased circulating 
granulocytes (Seckinger et al, 1987). This activity was suggested to be a direct effect 
of IL-1 and not mediated by IL-6. In rabbits or mice, IL-1 injection resulted in a 
dose-dependent granulocytosis and a significant increase in the number of circulating 
CFU-GM (Van Damme et al, 1986; Fibbe et al, 1988). Several evidences also 
showed that IL-1 acted synergistically with IL-3, IL-6, Stem cell factor (SCF), 
erythropoietin (EPO), G-CSF and GM-CSF on the induction of specific-lineage and 
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multilineage colonies (Garin et al, 2000; Spyridonidis et al, 1999; Emerson, 1996; 
David et al, 1995; Bohbot et al, 1995; Bmgger et al, 1993). In 5-fluorouracil-treated 
mice, IL-la enhanced the effect of G-CSF on reducing neutropenia and regeneration 
of colony-forming units of the erythroid, myeloid, and MK lineages in the bone 
marrow and spleen (Moore and Warren, 1987). Ex vivo expansion of CD34+ cells 
obtained from bone marrow and peripheral blood in the presence of IL-lp, IL-3, IL-6 
and SCF resulted in a significant expansion of total nucleated cells and CFU-GM 
(Garin et al, 2000). Treatment of bone marrow endothelial cells with IL-lp increased 
their adherence to CD34+ progenitor cell and MK cells, indicating that IL-ip might 
play a role in the trafficking of pluripotent stem cells (Rafii et al, 1994). 
Administration of IL-1 to mice which were treated with sublethal doses of irradiation 
accelerated the recovery of neutrophils and marrow reconstitution, accompanied by 
an increase of CFU-GM in the bone marrow (Gallicchio, 1988). IL-1 regulated the 
cell cycle of hematopoietic progenitor cells and protected early progenitor cells from 
radio- and/or chemotherapy in mice (Neta et al, 1987) and in human (Dalmau et al, 
1993). For the radio-protection effect, the mechanism could be mediated by the 
increased progression of the bone marrow cells to the late S phase (radioresistent 
phase) of the cell cycle, or by arresting bone marrow precursor cells in GO phase. 
For chemo-protection, the mechanism could be mediated by modulation of multiple-
drug resistant gene expression, like glutathione synthesis, which might reduce the 
sensitivity of bone marrow progenitor cells to drugs. This chemo-protective effect 
suggested a possible role of IL-1 in cancer therapy. 
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IL-1 a has been administrated to patients with refractory malignancies in a Phase I 
trial (Rosenthal et al, 1998). Results showed a significant increase in absolute 
neutrophil counts, a delayed but significant increase in platelet counts, and there was 
a marked increase in the number of CFU-G, CFU-M, CFU-GM, CFU-GEMM and 
BFU-E in the peripheral blood. A Phase I trial on IL-ip was also conducted in 
patients undergoing autologous bone marrow transplantation (BMT) for acute 
myelogenous leukemia (Nemunaitis et al, 1994). Administration of IL-lp before 
BMT resulted in the increase of absolute neutrophil counts and improved survival 
rate when compared with historical patients. However, there were toxicities included 
fever, chills, myalgia and headache after administration. 
IL-l(3-deficient mice procreated over 10 generations produced normal amounts of 
IL-1 a and was without evidence of hematologic impairment (Dinarello, 1996). They 
developed normally and were apparently healthy and fertile. The IL-ip-deficient 
mice responded normally in models of contact and delayed-type hypersensitively or 
following bacterial endotoxin lipopolysaccharide-induced inflammation (Zheng et al, 
1995). In contrast, when challenged with turpentine, which caused localized 
inflammation and tissue injury, the IL-ip-deficient mice exhibited an impaired acute-
phase inflammatory response and were completely resistant to fever development 
and anorexia (Horai et al, 1998). 
IL-1 a knockout mice developed normally, with decreased IL-1 (3 mRNA level (Horai 
et al, 1998). Fever induction upon injection with turpentine was suppressed in IL-
la/p doubly deficient mice, but not in IL-1 a knockout mice. 
7 
INTRODUCTION 
1.1.2 IL-1 receptor 
Two primary IL-1 receptors, IL-1 receptor I (IL-IRI) and IL-IRII, and one receptor 
accessory protein (IL-lRAcP) have been identified. The extracellular domains of the 
two receptors and the IL-lRAcP were members of the Ig superfamily. They were 
each composed of three IgG-like domains, and they shared a significant homology 
(Greenfeder et al, 1995; McMahan et al, 1991). In human, IL-IRI and IL-IRJI were 
distinct gene products, located on the long arm of chromosome 2 (Sims et al, 1995). 
IL-IRI and IL-IRII showed a modest 28% amino acid homology in their 
extracellular regions (approximately 320 amino acids) but differed markedly in their 
cytoplasmic tail (Sims et al, 1989; McMahan et al, 1991). Both IL-1 a and IL-ip 
bound to IL-1 receptors. IL-lp had the lowest affinity to IL-IRI when compared to 
that of IL-1 a and IL-IRA, but it bound more avidly to IL-IRII (Dinarello, 1996). 
1.1.2.1 IL-1 receptor I (IL-IRI) 
IL-IRI was an 80 kDa glycoprotein found prominently on endothelial cells, smooth 
muscle cells, epithelial cells, hepatocytes, fibroblasts, keratinocytes, epidermal 
dendritic cells and T lymphocytes (Dinarello, 1999). IL-IRI was heavily 
glycosylated. The blockage of the glycosylation sites reduced the binding of IL-1 to 
target cells (Mancilla et al, 1992). The failure to show specific and saturable IL-1 
binding was often due to the low numbers of surface IL-IRI on primary cells. In cell 
lines, the number of IL-IRI reached 5,000 per cell but primary cells usually 
expressed less than 200 receptors per cell (Shirakawa et al, 1987). IL-1 signal 
transduction has been observed in cells expressing less than 10 IL-IRI per cell 
(Stylianou et al, 1992). 
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As shown in Figure 1.1, IL-IRI had a single transmembrane segment and a 
cytoplasmic domain. The cytoplasmic domain of IL-IRI has no apparent intrinsic 
tyrosine kinase activity, but, when IL-1 was bound to a few receptors, the remaining 
unoccupied receptors appeared to undergo phosphorylation (Gallis et al, 1989), 
probably by a member of the MAP kinase family. 
IL-lRI-deficient mice were fertile and had no obvious developmental or 
immunologic defects. They appeared to lack any response to either IL-1 a or IL-1 (3 
(Labow et al, 1997). The mutant form of IL-IRI was associated with defective 
regulations of IL-1 receptor-associated protein (IRAK) activity and N F - K B activation, 
in response to IL-1 (3 (Croston et al, 1995). 
1.1.2.2 IL-1 receptor II (IL-IRII) 
IL-IRII was a 385 amino acid, 60-68 kDa transmembrane glycoprotein (McMahan et 
al, 1991; Liu et al, 1996), that was found in B cells (Colotta et al, 1994), 
keratinocytes (Groves et al, 1995), monocytes (Colotta et al, 1994), neutrophils 
(Colotta et al, 1995) and T-cells (McKean et al, 1993). IL-IRII did not form a 
complex with IL-IRI (Slack et al, 1993) and also did not transduce a signal (Sims et 
al, 1994). In human and mouse, IL-IRII had a short cytosolic domain consisting of 
29 amino acids (Bristulf et al, 1994). It appeared to act as a "decoy" molecule, 
particularly for IL-ip (Penton et al, 1997). The receptor bound tightly to IL-ip, thus 
preventing the binding of IL-1 (3 to IL-IRI (Colotta et al, 1993). 
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1.1.2.3 IL-1 receptor accessory protein (IL-lRAcP) 
Human IL-lRAcP was a 550 amino acid, 66 kDa transmembrane glycoprotein 
(Huang et al, 1997). IL-lRAcP had limited homology (�25o/o) to IL-IRI or IL-IRII 
(Yoon and Dinarello, 1998). Both the extracellular domain of the IL-lRAcP and its 
cytoplasmic segment shared homology with the IL-IRI (Greenfeder et al, 1995), 
which has been implicated in signal transduction and recruitment of IRAK to the IL-
IR complex. IL-lRAcP mRNA was constitutively expressed in a wide variety of cell 
types, such as astrocytes, endothelium, fibroblast and T cells (Wesche et al, 1997). Its 
expression correlated with IL-1 responsiveness. IL-1 RAcP-deficient mice were 
viable but unable to respond to IL-1 p. IL-1 RAcP-deficient fibroblasts could bind to 
IL-1 but failed to respond to the IL-1 agonist. Loss of IL-lRAcP expression 
differentially reduced the affinity of the IL-IRI for the different IL-1 ligands in these 
cells (Cullinan et al, 1998). 
1.1.3 IL-1 receptor antagonist (IL-1RA) 
A cDNA for IL-IRA was isolated from monocytes and found to code for a mature 
glycoprotein of 152 amino acid residues (Eisenberg et al, 1990). Approximately 25 
kDa in native molecular weight, it showed 26% amino acid sequence homology to 
human IL-ip and 19% homology to IL-1 a. IL-IRA inhibited IL-1 binding to cell 
surface receptors without inducing any detectable intracellular agonist effects (Figure 
1.1). After IL-IRA was bound to IL-lRI-bearing cells, there was no phosphorylation 
of the epidermal growth factor receptor (Dripps et al, 1991), a well-established and 
sensitive assessment of IL-1 signal transduction (Bird and Saklatvala, 1989). 
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Cells that were known to produce IL-IRA included corneal epithelial cells (Kennedy 
et al, 1995), monocytes (Lee et al, 1995; Wahl et al, 1993), neutrophils (Roberge et 
al, 1994; McColl et al, 1992), macrophages (Janson et al, 1991), and fibroblasts 
(Krzesicki et al, 1993; Silvera et al, 1995). IL-ip and IL-lRA production could 
occur in the same monocyte, but the proteins were regulated by different 
mechanisms. 
IL-IRA bound to both IL-IRI and IL-IRII with affinity comparable to IL-1 a or IL-
ip and effectively blocked IL-1 binding. Although IL-IRII was not a signaling 
receptor, IL-IRA bound to this receptor on neutrophils, monocytes, and B-cell lines 
with an affinity that was approximately 100- to 500-fold less than that for IL-IRI 
(Granowitz et al, 1991). Despite the near equal affinities of IL-1 and IL-IRA for IL-
IRI, a 10- to 100- fold molar excess of IL-IRA was often required to flood the 
system and block occupancy of only few receptors by IL-1 (Arend et al, 1990). 
IL-IRA was released in vivo during experimentally-induced inflammation and the 
natural course of diseases (Fischer et al, 1992). It was thus thought to be part of a 
naturally occurring mechanism that limited the extent of the potentially deleterious 
effects of IL-1 (Dinarello, 1991; 1993) (Table 1.2). 
The in vivo balance between endogenous IL-1 and IL-IRA appeared to be important 
in influencing the host response to infection (Hirsch et al, 1996). The IL-IRA 
knockout mice were smaller than wildtype controls, although no other overt 
phenotypic differences were described. Mice lacking endogenous IL-IRA were less 
susceptible to infection with Listeria monocytogenes than were the normal and 
transgenic mice, thus supporting the importance of IL-1 in resistance to infection. 
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The administration of IL-IRA reduced both the immunosuppression and the 
mortality of murine GVHD after bone marrow transplantation without impairing the 
engraftment of hematopoietic stem cells (McCarthy et al, 1991; Ferrara et al, 1992). 
In healthy human, sustaining a plasma level of 20 to 30 |ig/ml of IL-1 RA for several 
hours was not associated with hematologic changes, which was consistent with IL-
1 p-deficient mice (Granowitz et al, 1992). However, there was a 50% decrease in 
neutrophilia and circulating G-CSF levels when these volunteers were challenged by 
endotoxin (Granowitz et al, 1993). 
1.1.4 IL-1 p and inflammation 
Inflammation was the response of living tissue to injury or irritation. Trauma and 
damage to normal tissues resulted in the release of local chemical mediators which 
controlled the inflammatory response. Auxiliary cells, such as mast cells, basophils 
and platelets, released the vasoactive mediators histamine and 5-hydroxytryptamine, 
which induced vasodilution and vascular permeability (Higgs, 1989). Leukocyte 
accumulation and activation followed and they released chemotactic mediators, 
which controlled the accumulation and activation of neutrophils and monocytes. The 
presence of lymphocytes and plasma cells in inflamed tissues resulted in local 
antibody production and the involvement of the immune system. 
IL-1 was released from the inflammatory site at the initial stage of inflammation 
(Arend et al, 1985; Stem et al, 1985). It induced neutrophil accumulation (Cybulsky 
et al, 1988; Pettipher et al, 1986; Rampart and Williams, 1988) and stimulated 
leukocytes, fibroblasts, endothelial cells, synovial cells or osteoblasts to synthesize 
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prostaglandins E2 (Dayer et al, 1986; Dukovich et al, 1986; Zucali et al, 1986; 
Browning and Ribolini, 1987; Leizer et al, 1987) and prostaglandins I2 (Kawakami et 
al, 1986), which were potent vasodilutors and caused increased vascular permeability. 
Once lymphocytes and mononuclear cells started to accumulate, they were activated 
by IL-1 which enhanced cellular migration on the endothelium. IL-1 triggered vital 
host defense functions through activation of lymphocytes, B cell (Muraguchi et al, 
1984; Lipsky et al, 1983) and T cell (Mizel, 1982). 
Fever development was not induced in IL-ip knockout mice during an inflammatory 
response (Horai et al, 1998). IL-IRI knockout mice exhibited an attenuated 
inflammatory response when compared with the wild-type (Michael et al, 2000). In 
vivo administration of the neutralizing anti-IL-lRA antibodies to rabbits enhanced 
leukocyte accumulation, demonstrating the anti-inflammatory importance of 
endogenous IL-IRA (Arend et al, 1998). However, the production of IL-IRA in 
many inflamed tissues in human and animals might not be sufficient to completely 
neutralize the inflammatory effect of IL-1 (Williams et al 1998). A balance between 
IL-ip and IL-IRA was important in regulating inflammation. IL-lRA-deficient mice 




MK cells developed in the bone marrow from stem cells and gave rise to committed 
MK cells, which eventually fragmented into platelets (Figure 1.2). The more 
primitive burst-forming unit-MK (BFU-MK) had greater self-renewal capacity, 
whereas the more mature colony-forming unit-MK (CFU-MK) had lower 
proliferative potential (Han et al, 1991). Specific macromolecules were expressed 
during megakaryocytopoiesis. CD41 (GPIIb) was an early MK marker, and was 
expressed on bipotential erythroid-MK progenitors (Prandini et al, 1992) and 
committed MK progenitors (Levene et al, 1995; Berridge et al, 1985). The CD61 
(GPIIIa) antigen was expressed on MK cells, and resting and activated platelets 
(Modderman, 1989). In platelets, the CD41/CD61 (GPIIb/IIIa) complex was known 
as the receptor for fibrinogen, fibronectin, von Willebrand factor, platelet factor (PF)-
4 and thrombospondin (Ryo et al, 1983; Huang et al, 1982; Barber et al, 1972; 
Rabellino et al, 1981; Vinci et al, 1984), which was important for platelet adhesion 
and aggregation (Ryo et al, 1992). 
MK cells became polyploidy through endomitosis and average MK cells exhibited 
ploidy states of 4N to 28N (DuPont et al, 1983; Tanum and Engeset, 1983). The MK 
cell contained a smooth membrane system, which compartmentalized the platelet 
cytoplasm as small bud-like processes and were subsequently released into the 
circulation as platelets (Zucker-Franklin and Petursson, 1984). 
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1.2.1 Effects of cytokines on megakaryoytopoiesis 
Megakaryocytopoiesis, a complex and multi-stage cellular process, was regulated by 
cytokines such as thrombopoietin (TPO), interleukin-3 (IL-3), IL-6, IL-11 and 
granuolocyte macrophage-colony stimulating factor (GM-CSF). 
1.2.1.1 TPO 
TPO has been regarded as the most essential regulator for the growth and maturation 
of MK cells in the bone marrow. TPO increased the number of BFU-E and CFU-
GEMM from purified CD34+ progenitor cells (Tanimukai et al, 1997), suggesting 
that TPO not only influenced the MK/platelet lineage but also played a significant 
role in maintaining stem cells and other hematopoietic lineages. TPO has been 
reported to promote megakaryocytopoieis and thrombopoiesis. This included the 
commitment of hematopoietic stem cells to MK cells (Zeigler et al, 1994), 
proliferation of committed MK progenitor cells (de Sauvage et al, 1994; Kaushansky, 
1994; Wendling et al, 1994; Debili et al, 1995; Angchaisuksiri et al, 1996), 
differentiation of megakaryoblasts to MK (Zeigler et al, 1994; Debili et al, 1995; 
Angchaisuksiri et al, 1996) and platelet production from MK (Zeigler et al, 1994; 
Debili et al, 1995). When TPO was administrated to normal mice, it significantly 
increased the number of CFU-MK in the bone marrow and circulating platelet counts 
(Kaushansky, 1994; Farese et al, 1995). Knockout mice deficient in c-Mpl (TPO 
receptor) revealed 85% reduction in platelet counts without significant difference in 
red blood cell, total leukocyte, neutrophil and eosinophil counts (Gumey et al, 1994). 
An increased concentration of circulating TPO was also observed. 
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1.2.1.2 IL-3 
IL-3 was normally produced by T-lymphocytes and mast cells. IL-3 stimulated CFU-
MK colony formation from bone marrow and peripheral blood CD34+ cells 
(Dolzhanskiy et al, 1997; Catani et al, 1998). IL-3 stimulated preferentially on the 
early developmental stages of megakaryocytopoiesis and induced the in vitro 
proliferation and differentiation of MK progenitors from hematopoietic stem cells 
(Cardier et al, 1996). However, Dolzhanskiy et al (1998) showed that IL-3 inhibited 
further maturation of MK cells after endoreplication. IL-3, acted synergistically with 
IL-6, promoted platelet production in mice following 5-fluorouracil-mediated 
thrombocytopenia (Carrington et al, 1992). 
1.2.1.3 IL-6 
IL-6 appeared to act at the late stage of megakaryocytopoiesis in mice (Ishibashi et al, 
1989; Lotem et al, 1989) and human (Bruno and Hoffman, 1989; Kimura et al, 1990), 
affecting primarily the postmitotic MK developmental compartment. IL-6 was able 
to support MK cell maturation in the absence of other added growth factors (Imai et 
al, 1991; Ishibashi et al, 1989; Kimura et al, 1990). MK cells produced both IL-6 and 
IL-6 receptor (Navarro et al, 1991). Fragmentation of MK cell into platelets was 
stimulated by IL-6. IL-6 injected into mpl". mice restored the levels of MK cells and 
their progenitors in hematopoietic tissues and increased circulating platelets 
(Gainsford et al, 1998). Administration of IL-6 to mice increased their peripheral 
platelet production, as well as MK- and GM- colony forming cells in the bone 
marrow and spleen (Hill et al, 1990). Autologous bone marrow transplant recipients 





The stromal origin of IL-11 rendered it capable of hematopoietic and lymphopoietic 
activities. IL-11 potentiated human and murine MK cell development in vitro with an 
increase in the MK cell ploidy and it acted synergistically with IL-3 to stimulate 
megakaryocytopoiesis (Bruno et al, 1991; Burstein et al, 1992). In vivo, IL-11 
induced an increase in platelet counts and the polyploidy level of murine bone 
marrow MK cells (Yonemura et al, 1993; Leonard et al, 1996). Recombinant IL-11 
stimulated a modest thrombocytosis in normal mice, and accelerated both neutrophil 
and platelet recovery after cytotoxic chemotherapy, with or without bone marrow 
transplantation (Neben et al, 1993). 
1.2.1.5 GM-CSF 
GM-CSF had a stimulatory effect on MK colonies in vitro (Kaushansky et al, 1986; 
Mazur et al, 1987). Expressions of GM-CSF and GM-CSF receptor were identified 
on primary human bone marrow MK cells (Jiang et al, 1994; Aglietta et al, 1991). In 
vzvo studies in animals showed that GM-CSF enhanced the MK ploidy, (Tomer et al, 
1993) and MK maturation (Stahl et al, 1991), but not platelets. Administration of 
GM-CSF into patients with normal hematopoiesis increased CFU-MK but not 
accompanied by enhanced platelet production (Aglietta et al, 1991), unless other 
cytokines such as IL-3 was also administered (Bretti et al, 1996; Farber et al, 1997). 
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1.2.2 Megakaryocytopoiesis and IL-lp 
Primary bone marrow MK cells and MK cell lines secreted IL-ip (Jiang et al, 1994). 
IL-lp was capable of enhancing the ability of IL-3 to promote BFU-MK-derived 
colony formation (Briddell and Hoffman, 1990), long-term megakaryocytopoiesis 
(Briddell et al, 1992), production of MK, production and release of platelets into the 
peripheral blood (Monroy et al, 1991). IL-lp in combination with TPO significantly 
enhanced the ex vivo expansion of MK progenitors from CD34+ cells (van den 
Oudenrijn et al, 1999; Williams et al, 1998; Su et al, 2001). Administration of IL-1 p 
to mice suppressed mature erythroid progenitors but increased the number of spleen 
and marrow immature erythroid, macrophage, granulocyte, precursor cell of 
circulating platelets and CFU-MK (Briddell et al, 1992; Williams et al, 1989). 
Repeated injections of IL-1 (3 induced thrombocytosis in mice (Kimura et al, 1990), 
possibly mediated by the high serum levels of IL-6 (Dan et al, 1995). 
IL-ip stimulated human circulating platelet production in patients with metastatic 
malignant disorders (Tewari et al, 1990). Although this effect might be due to the 
synergy with IL-ip, IL-3 and IL-6, no changes in plasma IL-3 and IL-6 levels were 
observed. High serum levels of IL-1 (3 and platelet counts were observed in 
rheumatoid arthritis patients with thrombocytosis (Ertenli et al, 1996). IL-1 (3 
increased platelets in animals and human after irradiation or myelosuppressive drugs 




The effect of IL-ip in the MK lineage has been suggested to be indirect. In MK 
progenitor cells, IL-lp induced DNA synthesis was inhibited by neutralizing anti-
tumor necrosis factor (TNF) and anti-GM-CSF antibodies (Bot et al, 1990). Addition 
of IL-1 p to normal human bone marrow CD34+ cell culture, in the presence of IL-6, 
promoted CFU-MK (Bruno et al, 1991). However, this effect was totally abolished 
by the addition of anti-IL-6, anti-IL-ip or anti-IL-3 antisera, suggesting that IL-ip 
and IL-6 acted in concert on promoting the de nono synthesis of IL-3 and CFU-MK 
formation. In the presence of IL-6 neutralizing antibody, IL-ip failed to evoke a 
proliferative response on purified megakaryoblasts obtained from patients with acute 
megakaryoblastic leukemia (Brach et al, 1990). 
1.2.3 Megakaryocytopoiesis and inflammation 
Activated platelets released inflammatory mediators, such as their a granule proteins 
and TGF-p, and they adhered to injured endothelial cells and interacted with 
leukocytes in modulating the inflammatory reaction (Matthias, 1991). 
Thrombocytosis was commonly associated with various acute and chronic 
inflammatory diseases and occurred in experimentally-induced inflammation in mice 
and rabbits (Abildgaard et al, 1967; Avraham et al, 1993; Hoffman, 1989). 
Activation of endothelial cells by inflammatory cytokines such as IL-1 (3, TNF-a, or 
IFN-y could potentiate MK cells adhesion to endothelial cells (Avraham et al, 1993). 
During inflammation, the production of cytokines such as IL-ip might initiate a 
cascade of reactions including T cell activation, release of IL-2, induction of MK-
CSF, IL-3 and GM-CSF, leading to an activation of megakaryocytopoiesis 
(Hamaguchi et al, 1990). 
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1.3 Signal transduction pathway of the megakaryocytic lineage: 
transcription factors 
In the MK lineage, the induction of transcription factors in response to IL-lp has not 
been reported. GATA-1 and NF-E2 were few known transcription factors that were 
functionally-linked to the MK lineage (Romeo et al, 1990). The signal transduction 
pathway of this lineage has been largely studied by the stimulation of TPO (Figure 
1.3). 
1�3.1 GATA-1 
The GATA family was composed of 6 members: GATA-1, GATA-2, GATA-3, 
GATA-4, GATA-5 and GATA-6 (Weiss and Orkin, 1995), which consisted of 2 
highly conserved zinc finger domains. The carboxyl (C) finger was absolutely 
required for DNA binding, whereas the amino (N) finger stabilized the DNA binding 
and conferred full specificity (Martin and Orkin, 1990; Yang and Evan, 1992). 
GATA-1 was identified as an erythroid nuclear protein that bound to the consensus 
GATA motif, (A/T)GATA(A/G), in globin gene promoters, enhancers, and locus 
control regions. GATA-1 was expressed at high levels in erythroid cells, MK cells, 
mast cells and at lower levels in hematopoietic progenitor cells (Weiss et al, 1995). 
GATA-1 was not only a major regulator of the transcription of erythroid genes, it also 
regulated the expression of several MK-restricted genes, such as CD41 (GPIIb) 
(Lemarchandel et al, 1993). A multitype zinc finger protein named Friend of GATA-1 
(FOG) co-expressed with GATA-1 in MK cells and cooperated during MK 
differentiation (Tsang et al, 1997). FOG might be a cofactor for GATA-1. The C 




In chimeric mice generated from mutant embryonic stem (ES) cells lacking GATA-1, 
the mutant cells did not promote erythropoiesis (Pevny et al, 1991). In addition, 
GATA-1-null ES cells were unable to differentiate into mature erythroid cells in vitro 
(Weiss et al, 1994; Weiss and Orkin, 1995). Thus, GATA-1 was considered to be 
essential for the terminal differentiation of erythroid progenitor cells. Shivdasani et 
al (1997) demonstrated that a targeted mutation of the regulatory element within the 
GATA-1 locus led to a lineage-selective loss of expression but sufficient erythroid 
cell levels to avoid lethal anemia. The mutant mice had markedly reduced platelet 
numbers, deregulated MK cell proliferation and severely impaired cytoplasmic 
maturation. Takahashi et al (1998) reported that lineage-selective GATA-1 knockout 
mice exhibited striking thrombocytopenia and severe anemia, which were 
accompanied by the increased proliferation and impaired cytoplasmic maturation of 
MK cells. These results further suggested that GATA-1 played essential roles not 
only in erythropoiesis but also in megakaryopoiesis and thrombopoiesis. 
1.3.2 NF-E2 
NF-E2 was a heterodimeric nuclear protein comprised of two polypeptide chains, a 
hematopoietic-specific 45 kDa subunit (p45) and pi8 subunit that was related to the 
v-Maf oncogene. Both proteins belonged to the basic-leucine zipper family of 
transcription factors (Andrews et al, 1993). NF-E2 bound to the consensus sequence 
TGCTGA(G/C)TCA(T/C) found in several erythroid-specific promoters and in the 
a- and P-globin locus control regions (LCR) (Andrews et al, 1993; Talbot et al, 1991; 
Gong et al, 1996). Within the NF-E2 recognition site was the sequence 
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TGA(G/C)TCA which was recognized by the transcription factor AP-1 (c-Jun/c-Fos). 
The regulation of NF-E2 activity involved both DNA binding and transactivation 
activities, which were regulated by serine/threonine phosphorylation such as a Ras 
signaling cascade (Nagai et al, 1998). Expression of p45 NF-E2 was restricted to 
erythroid precursors, MK cells, mast cells, and multipotential progenitors. Functions 
of NF-E2 in megakaryocytopoiesis included the regulation of cytoplasmic maturation, 
granules formation and platelet development (Shivdasani and Orkin, 1995). NF-E2 
has been shown to bind to the promoter and to regulate the expression of a 
megakaryocytic gene viz thromboxane synthase (Shivdasani, 1997). 
NF-E2 knockout mice displayed an unexpectedly mild diserythropoiesis (Shivdasani 
and Orkin, 1995). Alterations to the erythroid compartment were most pronounced in 
neonates where anemia, dysmorphic red cells, and decreased hemoglobin content 
were observed. An absence of circulating platelets, which led to the death due to 
hemorrhage, was also observed in these knockout mice. Mice lacking p45 NF-E2 
exhibited profound thrombocytopenia resulting from a maturation arrest of MK cells 
(Shivdasani and Orkin, 1995). MK cells were present but they had profound 
cytoplasmic abnormalities, including a dramatic reduction in granule numbers, 
disorganized demarcation membranes, and a failure to delimit platelet territories. 
Although MK cells in these mice could respond to thrombopoietin, they failed to 
produce platelets, suggesting that NF-E2 was required in the late stages of 




1.4 IL-lp signaling 
IL-1 affected a wide range of cellular compounds including numerous growth factors, 
protein kinases and transcription factors in various cell types (Dinarello，1996, 1991; 
Bankers-Fulbright et al, 1996). In the MK lineage, the signal pathway of IL-1 p has 
not been reported. 
The best-described signaling cascade initiated by IL-lp involved a trimeric protein 
complex of IL-1 P, IL-IRI and IL-lRAcP. IL-IRI was phosphorylated at serine and 
threonine residues after IL-1 (3 binding (Gallis et al, 1989). In primary cells, the 
number of IL-IRI was very low (< 100/cell)，and a biologic response occurred when 
only as few as 2-3% of IL-IRI receptors were occupied (Gallis et al, 1989; Ye et al, 
1992). Extensive "amplification" took place after the initial post-receptor binding 
event, probably by multiple and sequential phosphorylations (or dephosphorylations) 
of kinases. Two nuclear factors have been shown to be IL-1 inducible: NF-KB 
(Shirakawa and Mizel, 1989) and AP-1 (Muegge et al, 1989) (Table 1.2). 
IL-ip activated at least four protein kinase cascades. One cascade involved IRAK 
and TNF-receptor-associated factor 6 (TRAF6) associated with the IL-1 receptor 
complex. Other three pathways involved the mitogen-activated protein kinase 
(MAPK), namely p42/44 extracellular signal-regulated protein kinase (ERK), p38 
MAPK, and the stress-activated protein kinase that phosphorylated the N-terminal 
region of c-Jun (SAPK/JNK) (Andrea et al, 1998) (Figure 1.4). 
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1.4.1 Activating protein-1 (AP-1) 
The AP-1 family of transcription factors consisted of homodimers and heterodimcrs 
of Jiin (v-Jun, c-Jiin, JunB, JunD), Fos (v-Fos, c-Fos, FosB, Fral, Fra2) or activating 
transcription factor (ATF2, ATF3/LRF1, B-ATF) basic region leucine zipper (bZIP) 
proteins (Vogt and Bos, 1990; Angel et al, 1991). AP-1 activation might be mediated 
by transcriptionally independent or dependent mechanisms, involving post-
translational modifications of its components or increase in the expression of their 
corresponding genes (Karin, 1995). 
1.4.1.1 Structure and function of c-Jun and c-Fos 
1.4.1.1.1 DNA-binding domain 
c-Jun and c-Fos belonged to the bZIP superfamily of transcription factors, which 
dimerized and bound to DNA via their basic/leucine zipper (BZIP) region 
(Kouzarides and Ziff, 1989; Gentz et al, 1989; Schuermann et al, 1989; Turner and 
Tjian, 1989). 
1.4.1.1.2 Dimerization 
The leucine zipper dimerization interface provided a surface for multiple interactions. 
The c-Jun protein could form either homodimers or heterodimers with c-Fos; c-Fos 
itself was unable to form homodimers (Ziff, 1990; Matsui et al, 1990; Hai and 
Curran, 1991; Hsu et al, 1991; Dorsey et al, 1995; Kouzarides and Ziff, 1989). Jun-
Fos heterodimers were more stable than Jun-Jun homodimers and showed an 
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increased affinity for AP-1 binding and more efficient transcriptional activations 
(Chiu et al, 1988; Sassone et al, 1988). Jun-Fos complexes were found only in the 
cell nucleus (Curran et al, 1984). 
1.4.1.1.3 DNA-binding 
A region in bZIP domain rich in basic amino acids and located next to the N-terminal 
was responsible for sequence-specific DNA binding (Nakabeppu and Nathans, 1989; 
Kouzarides and Ziff, 1989; Glover and Harrison, 1995). Jun-Jun and Jun-Fos dimers 
preferentially bound to the phorbol 12-0-tetradecanoate-13-acetate (TPA)-responsive 
element (TRE; this element has the base sequence TGACTCA). 
1.4.1.1.4 Regulation and function of c-Jun 
The c-Jun gene was expressed in many cell types at low levels, and its expression 
was elevated in response to many stimuli, including growth factors, cytokines and 
UV irradiation (Karin, 1995). The expression c-Jun could be regulated at the 
transcriptional, post-transcriptional, and post-translational levels. The site for the 
transcriptional regulation was located in the 5' noncoding sequences of c-Jun and 
consisted of the SP-1 binding site, CAAT box, and the AP-1 binding site. The 
important feature of this control system was that Jun transcription was auto-regulated 
by Jun/AP-1 itself: binding of the Jun/AP-1 protein to the AP-1 site increased 
transcription (Angel et al, 1988). 
25 
INTRODU TION 
The transcriptional activity of c-Jun was enhanced by amino-terminal 
phosphorylation on serine 63/73 (Pulverer et aI, 1991; Smeal et aI, 1991). This 
inducible phosphorylation was mediated by members of the Jun amino-terminal 
kinase (JNK) subfamily (Hibi et aI, 1993; Derijard et aI, 1994; Kyriakis et aI, 1994) 
and was required to recruit the transcriptional coactivator cAMP response element-
binding (CREB) protein (CBP) (Arias et aI, 1994; Bannister et aI, 1995). 
c-Jun was essential for normal mouse development (Kerppola and Curran, 1996; 
Johnson et aI, 1993). Primary fibroblasts from c-Jun-I- embryos were completely 
defective in their proliferation (Johnson et aI, 1993). Heterozygous mutant mice 
appeared normal, but embryos lacking c-Jun died at mid- to late-gestation and 
exhibited impaired hepatogenesis, altered fetal liver erythropoiesis and generalized 
oedema (Hilberg et aI, 1993). The c-Jun-I- ES cells participated efficiently in the 
development of somatic cells except liver cells, further suggesting an essential 
function of c-Jun in hepatogenesis. 
1.4.1.1.5 Regulation and function of c-Fos 
Several cis elements mediated c-Fos induction. Proximal to the c-Fos TATA box was 
a CRE that was likely to be occupied by CREB (CRE-binding protein) or ATF 
proteins, c-Fos induction was mediated via cAMP- and Ca2+ -dependent signaling 
pathways in response to neurotransmitters and polypeptide hormones (Sheng et ai, 
1991). Another cis element that regulated c-Fos transcription was a Sis-inducible 
enhancer (SIE), which was recognized by the Signal transducer and activator of 
transcription (STAT) group of transcription factors (Darnell et ai, 1994). The STATs 
were activated and translocated to the nucleus in response to signals which activated 
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the Janus kinase group of tyrosine kinases (Darnell , 1996). A third cis element wa 
the serum-response element (SRE), which was recognized by a dimer of the serum-
response factors that recruited the monomeric ternary complex factors (TCF) 
(Treislnan, 1992). SRE were important mediators of c-Fos induction by a large 
variety of extracellular stimuli, such as DV irradiation and IL-l (Devary et ai, 1991; 
Whitmarsh et ai, 1995; Raingeaud et ai, 1995). 
Homozygous c-Fos-1- mice, although viable, were growth-retarded and developed 
osteopetrosis and deficiencies in bone remodeling and tooth eruption (Johnson et ai, 
1992). Overexpression of c-Fos in bone tissues resulted in development of 
osteosarcomas (Wang et aI, 1995). Moreover, overexpression of c-Fos in transgenic 
animals resulted in a dysregulation of bone growth (Ruther et aI, 1987) and eventual 
chondrosarcomas (Ruther et aI, 1989), as well as an alteration of the maturation rates 
of T lymphocytes (Ruther et aI, 1988). 
1.4.1.4 AP-l in IL-l ~ signaling 
IL-l ~ has been reported to regulate AP-l components post-translationally and by 
inducing Jun-family gene expression (McKean et ai, 1994; Baumann et ai, 1991 ). In 
addition, the Fos family members c-Fos, FosB and Fra-l have been reported to be 
transcriptionally upregulated in T cells in response to IL-l ~ (Yoza et ai, 1992). 
Increased mRNA levels of c-Jun in T helper lymphocytes and human hepatoma cell 
line HepG2 (McKean et aI, 1994; Muegge et ai, 1989; 1993) as w'ell as c-Fos in 
HepG2 cells (Muegge et ai, 1993) occurred soon after IL-l ~ stimulation. IL-l ~ 
treatment in gingival fibroblasts, HepG2 cells and CHO cells resulted in the 
activation of INK (Bird et ai, 1994; Whitmarsh et aI, 1995), which potentiated the c-
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Jim transactivation function. IL-ip has been reported to stimulate ERK- and JNK-
mediated phosphorylation of the TCF family transcription factors Elk-1 and SAP-1 
in CHO cells, which regulated c-Fos expression (Whitmarsh et al, 1995). 
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P / B . 
口 n I T W e n r P • r P n = ] n = ] 
fe I , 膽 詹 r i 
^ � IL-IRQ I 
\ \ \ \\ y 人 
O) Signal IL-IRI U IL-IRI U 
i IL-mAcP = 二inity signal 
No Signal A B C D E Figure 1.1 — Interleukin-1 p (IL-1 p) and interleukin-1 receptor cell signaling 
(Dinarello, 1996). 
A IL-1 receptor antagonist inhibited signal t ransduct ion. 
B IL-1 receptor accessory protein (IL-lRAcP). 
C No signal transduction occurred when IL-1 was bound to IL-IRI 
in the absence of IL-lRAcP. 
D Signal transduction was triggered when IL-IRI was bound 
to IL-1 in the presence of IL-lRAcP. 
E IL-1 receptor II (IL-IRII), a decoy protein, did not trigger 
signal transduction when bound to IL-1. 
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Figure 1 .2 - Megakaryocytopoiesis. 
MK cells were developed from stem cells in the bone marrow. 
During the d i f f e ren t i a t ion process , several c lasses of MK 
progenitor cells have been functionally defined. MK maturation 
was marked by an increase in size, the development of organelles 
and acquis i t ion of p la te le t p ro te ins such as CD41/ CD61 
(glycoproteins Ilb/IIIa) (GPIIb/IIIa), GPIb, thrombospondin (TSP), 
von Wi l lebrand fac tor (vWF) and p la te le t fac tor 4 (PF4). 
Megaka ryocy topo ie s i s has been con t ro l l ed by a complex 
network of interacting cytokines including interleukin (IL)-3, IL-6, 
IL-11, g r anuo locy t e - co lony s t imu la t ing f ac to r (G-CSF) , 
erythropoietin (EPO) and thrombopoietin (TPO) (Kaushansky, 1998). 
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Wj / / I ^ ^ ^ J 
STATs 1,3,? / 
^ ^ ^ / k 
X 4 ofos • X 
( ？?? GATA-1 � 
NUCLEUS NF-E2 
Figure 1.3 - A model of TPO and Mpl signaling. 
Phosphorylation of STATS and possibly STATl and STAT3, SHC, and 
other members of the MAPK pathway were involved in the response to 
TPO (Kaushansky, 1997). GATA-1 and NF-E2 have been shown to be 
involved in the TPO signaling in the MK lineage (in dot-line). 
Abbreviation: JAK2, Janus tyrosine kinase 2; TYK2, Tyrosine kinase 2; 
GAP, GTPase activating protein; RAS, Rat sarcoma virus; STAT, Signal 
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Figure 1 . 4 - A model of IL-1 (3 signal transduction. 
Induction of N F K B was ini t ia ted by the direct interact ion of 
theY496 EKM sequence in IL- IRI (Luke and Catherine, 1998; 
Kimberly et al, 1998; Holger et al, 1997; Shrikanth et al, 1997). 
I L - l p a c t i v a t e d S A P K / J N K , p38 and ERK p r o t e i n k inase 
cascades, through the p i 10 catalytic unit of PI kinase (Andrea 
et al, 1998; Shr ikan th et al, 1997; S i z e m o r e et al, 1999). 
Crosstalk interaction between signaling pathways might occur. 
Phosphorylation 
• Crosstalk interaction 
Abbreviation: PI kinase, Phosphatidylinositol kinase; MyD88, Myeloid 
differentiation protein; IRAK, IL-lRI-associated kinase; ATP, 
Adeonine triphosphate; ADP, Adeonine diphosphate; TRAF6, 
TNF-receptor-associated factor 6; NIK, NFKB-inducing kinase; 









Bone marrow stimulation 
Tumor necrosis 
Immunological effects 
T cell activation 
IL-2 production 
Increased IL-2 receptors 
B cell activation 
Synergism with IL-4 
Induction and synergism with IL-6 
Activation of natural killer cells 
Synergism with IL-2, interferons, on natural killer cells 
Increased lymphokine production (IL-3, IL-6, interferon-gamma) 
Macrophage cytotoxicity 
Growth factor for B cells 
Increased IL-1 production 
Table 1.1 - Hematological {in vivo) and immunological 
{in vitro) effects of recombinant IL-1 (Dinarello, 1993). 
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Effects of IL-1 RA on local inflammation 
Decreased neutrophil accumulation in inflammatory peritonitis in mice 
Reduction in immune complex-induced neutrophil infiltration, eicosanoid 
production, and tissue necrosis in rabbit colitis 
Reduction in acid-induced neutrophil infiltration and enterocolitis in rats 
Decreased endotoxin-induction intestinal secretory diarrhea in mice 
Reduction in ischemia and excitotoxic-induced brain damage in rats 
Decrease in number of necrotic neurons in cerebral artery occlusion 
Inhibition of permanganate-induced granulomas in rats 
Inhibition of LPS-induced intra-articular neutrophil infiltration 
Decreased IL-1-induced synovitis and loss of cartilage proteoglycan 
Reduced myocardial neutrophil accumulation after coronary occlusions in 
dogs 
Reduced inflammation and mortality in acute pancreatitis 
Decreased hepatic inflammation after hemorrhagic shock 
Table 1.2 - Effects of interleukin-1 receptor antagonist 
( I L - l R A ) on i n f l a m m a t i o n ( D i n a r e l l o , 1999) . 
These effects have been demonstrated by administration 
of recombinant IL-IRA to animals. 
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IL-1 SIGNAL TRANSDUCTION PATHWAYS 
GENE FACTORS* INVOLVED** NOT INVOLVED** 
Fos NF-IL-6 PKC cAMP 
Jim AP-1 PLA2, PTK PKC 
G-CSF NFkB, NF-IL-6 -- --
GM-CSF AP-1, NFkB -- cAMP 
IL-lbeta NFkB, NF-IL-6 MAPK, PKC, PTK cAMP, PKC 
IL-2 AP-1, NFkB ROI cAMP, G-protein, PKC 
IL-4 none Ca?., PKA, PKC PKC 
IL-5 none cAMP, PKA, PKC -
IL-6 AP-1, NFkB, NF-IL-6 MAPK, PLA2, PKC, PTK cAMP, PKA, PKC 
IL-8 AP-1, NFkB, NF-IL-6 -- PKC, acid-SMase 
TNFalpha AP-1, NFkB, NF-IL-6 PKC -
Table 1.3 - Genes and signal transduction pathways proposed 
to be regula ted by IL-1 (Bankers -Fu lb r igh t et al, 1996). 
Abbreviations: PKC, Protein kinase C; PLA� ’ Phospholipase A�； 
PTK, Protein tyrosine kinase; ROI, Reactive oxygen intermediates; 
Acid-SMase, Acidic sphingomyelinase; PKA, Protein kinase A. 
-- No information available. 
* Transcription factor binding consensus sequences shown 
to be in promoter and/or transcription factors shown to be 
involved in gene induction but promoter not cloned; 
not necessari ly involved in IL-1 induct ion of gene. 
None Promoter examined but no AP-1, N F K B or NF-IL-6 sites 
identified. 
** Signaling pathways examined and shown to be involved 
in or not involved/inhibitory in IL-1 induction of the 
gene; pa thways were not n e c e s s a r i l y invo lved in 
the IL-1 induction of the transcription factors listed. Co-





There are three main objectives in this project. 
1. To investigate the effect of IL-ip on the proliferation of megakaryocytic cells 
and to identify the expression of IL-1 receptor I and II on human 
megakaryocytic cell lines and primary megakaryocytes. 
Proliferative effect of IL-ip on primary MK cells was measured by CFU-MK 
assay using human cord blood and murine bone marrow cells. The mRNA and 
protein expressions of IL-1 receptors (I and II) in human primary MK cells and 
MK cell lines were performed using RT-PCR, Southern blot analysis, flow 
cytometry and immunofluorescence staining. 
2. To investigate the signal transduction pathway of IL-ip in the activation of 
transcription factors c-Jun, c-Fos, GATA-1 and NF-E2. 
The effects of IL-1 (3 on the mRNA and protein expressions of c-Jun, c-Fos, 
GATA-1 and NF-E2 in MK cell lines Meg-01 and CHRF were studied. Dose-
responses and duration effects of IL-lp on these transcription factors were 
investigated using RT-PCR, Southern blot and Western blot analyses. 
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3. To establish the mechanism of IL-ip on the activation of the sign a且 
transduction pathway: effects of recombinant human IL-1 receptor 
antagonist (IL-IRA), human TPO neutralizing antibody (TPO Ab), 
actinomycin D (ActD) and cycloheximide (CHX) on the nuclear 
accumulations of c-Jun, c-Fos, GATA-1 and NF-E2. 
To confirm the direct effects of IL-lp on the signal pathway were via its 
"functional" receptors, IL-IRA was added to CHRF cells. TPO Ab was added to 
CHRF cells to neutralize possible effects of endogenous TPO present in the 
culture serum or secreted by the MK cells. In addition, RNA synthesis inhibitor 
ActD and protein synthesis inhibitor CHX were added to CHRF cells to 
determine the mechanism of the increased levels of mRNA and proteins of the 
transcription factors as stimulated by IL-1 p. Those studies were performed using 
RT-PCR, Southern blot and Western blot analyses. 
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r N THE ROLE AND MECHANISM OF THE PRO-INFLAMMATORY CYTOKINE 
IL-IBETA ON MEGAKARYOCYTOPOIESIS: THE EXPRESSION OF IL-1 
RECEPTORS AND SIGNAL TRANSDUCTION PATHWAY 
V J 
iz  
(1) Effects of IL-1 P on proliferation 
-Murine and human CFU-MK \ y . ^ s (2) Detection of IL-1 receptors (IL-IRI & RII) 
-RT-PCR, Southern blot, flow cytometry and morphology studies  y 
\ / 
f ： \ J 4 (3) Signaling pathways \ / 
-c-Jun, c-Fos, GATA-1 & NF-E2 ^ “ �^ “ i • TT _ (4) Functional receptors and direct effects 
RT-PCR, Southern & Western blots a j j ‘ . tt i n a / ‘ 丄 �� 
-Addition 01 IL-lRA (receptor antagonist) ~~ - Addition of TPO neutralizing antibody 
. ： ^ X 
(5) Mechanism of activation 
-Addition of ActD & CHX — 
-RT-PCR, Southern and Western blots 
V J 
40 
MATERIALS AND METHODS 
CHAPTER THREE 
MATERIALS AND METHODS 
3.1 Effects of IL-ip on the growth and development of megakaryocytic 
progenitor cells 
3.1.1 Murine colony-forming unit-megakaryocyte (CFU-MK) assay 
3.1.1.1 Murine bone marrow harvest 
3.1.1.2 Treatment with IL-1 p 
3.1.1.3 Murine CFU-MK assay 
3.1.2 Human colony-forming unit-megakaryocyte (CFU-MK) assay 
3.1.2.1 Cord blood collection and selection of CD34+ stem cells 
3.111 Treatment with IL-1 (3 
3.1.2.3 Human CFU-MK culture 
3.1.3 Calculations of CFU-MK 
3.1.4 Effects of IL-1 p on the Meg-01 cell growth 
3.2 Detection of mRNA expressions of IL-1 receptors (IL-IRI and IL-IRII) in 
human megakaryocytic cell lines and primary cells 
3.2.1 Cell culture 
3.2.1.1 Human cell lines 
3.2.1.2 Ex vivo expansion of megakaryocytic progenitors from 
enriched CD34+ stem cells 
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3.2.2 Reverse transcription-polymerase chain reaction (RT-PCR) and 
Southern blot analysis 
3.2.2.1 Extraction of total cellular RNA 
3.2.2.2 RT-PCR 
3.2.2.3 Gel electrophoresis and alkaline transfer of RT-PCR 
products 
3.2.2.4 Southern blot analysis and detection 
3.3 Detection of protein expressions of IL-1 receptors (IL-IRI and IL-IRII) in 
human megakaryocytic cell lines and primary cells 
3.3.1 Flow cytometry detection 
3.3.2 Immunofluorescence staining of human bone marrow megakaryocytic 
cells 
3.3.2.1 Primary megakaryocytic cells from human bone marrow 
3.3.2.2 Immunofluorescence staining 
3.4 Effects of IL-1 p on the expressions of c-Jun, c-Fos, GATA-1 and NF-E2 in 
human megakaryocytic cell lines 
3.4.1 Dose-dependency effect of IL-1 p on the expression of transcription 
factors 
3.4.2 Time-course effect of IL-1 (3 on the expression of transcription factors 
3.4.3 mRNA expressions of transcription factors after IL-1 (3 treatment 
3.4.4 Protein expressions of transcription factors after IL-lp treatment 
3.4.4.1 Preparation of total protein extract 
3.4.4.2 Preparation of nuclear protein extract 
3.4.4.3 Measurement of protein concentration 
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3.4.4.4 Preparation of SDS-PAGE 
3.4.4.5 Gel electrophoresis and membrane transfer 
3.4.4.6 Western blotting and detection 
3.5 Mechanism of activation of the signal transduction pathway by IL-1 P on 
human megakaryocytic cell line CHRF-288-11 
3.5.1 Effects of IL-1 receptor antagonist on the nuclear accumulation of c-
Jun, c-Fos, GATA-1 and NF-E2 induced by IL-lp 
3.5.2 Effects of TPO neutralizing antibody on the nuclear accumulation of 
c-Jun, c-Fos, GATA-1 and NF-E2 induced by IL-lp 
3.5.3 Effects of actinomycin D and cycloheximide on the nuclear 
accumulations of c-Jun, c-Fos, GATA-1 and NF-E2 induced by IL-1 (3 
3.6 Statistical Analysis 
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CHAPTER THREE 
MATERIALS AND METHODS 
3.1 Effects of Interleukin-ip (IL-ip) on the growth and development of 
megakaryocytic progenitor cells 
3.1.1 Murine colony-forming unit- megakaryocyte (CFU-MK) assay 
3.1.1.1 Murine bone marrow harvest 
Female, BALB/C mice (6-8 week-old) were killed by cervical dislocation. The 
femurs were removed and cut at both ends. Size 21-23 needles were used to expel the 
bone marrow cells with 2 ml of Iscove's modified dulbecco's medium (IMDM) 
(Gibco; NY, USA) into a centrifuge tube. These cells were washed twice by 
centrifugation in IMDM at 300 g for 10 min at room temperature. About 5-10x10^ 
total nucleated cells were obtained from each mouse. Viability of cells was evaluated 
by trypan blue exclusion staining using 1:4 dilution of trypan blue solution (Gibco). 
Dye-exclusion counting was performed by a bright-line hematocytometer (Reichert-
Jung, Cambridge instruments incorporation; Buffalo, NY, USA). The viability was 
reported as the percentage of viable cell in a total of 200 cells counted. 
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3.1.1.2 Treatment with IL-1 (3 
The effect of IL-1 (3 on thrombopoietin (TPO)-mediated CFU-MK formation was 
studied by the addition of IL-1 (3 (0-50 ng/ml) to the culture system (section 3.1.1.3) 
with or without TPO (20 ng/ml). To compare the effect of various cytokines on 
murine CFU-MK formation, IL-ip, interleukin-3 (IL-3), interleukin-6 (IL-6), stem 
cell factor (SCF) or Flt-3-ligand (Flt-3L) were added to the culture at 20 ng/ml with 
or without TPO (20 ng/ml). The effect of IL-1 (3 was compared with that of TPO, IL-3 
and IL-6 on murine CFU-MK formation by the addition of 20 ng/ml of each cytokine 
to the culture (2x10^ cells). The concentrations of individual cytokines have been 
optimized in a previous pilot study (Li et al, 2000). All cytokines were purchased 
from PeproTech (London, England). 
3.1.1.3 Murine CFU-MK assay 
Murine bone marrow cells were cultured in Petri dishes (35mm) using the plasma-
clot culture method. The system contains 2x10^ total nucleated cells, 1% deionized 
bovine serum albumin (BSA) (Sigma; Saint Louis, USA), 0.34 mg calcium chloride, 
10% citrated bovine plasma (Sigma), 100 U penicillin (Gibco), 50 jug streptomycin 
(Gibco), various cytokine combinations and IMDM in a total volume of 1 ml. The 
dishes were incubated in duplicate at 37�C in a fully humidified atmosphere with 5% 
CO2. After 7 days of culture, the clots were dried in situ with filter papers and fixed 
with 1% paraformaldehyde in 0.1 M sodium phosphate buffer (pH 6) for 15 min at 
room temperature. Then it was washed with 0.1 M sodium phosphate buffer (pH 6) 
and stained for acetylcholine esterase (AChE) to detect MK colony using AChE 
staining solution (0.1 M phosphate buffered saline pH 6, 50 mg acetyl-thiocholine 
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iodide, 0.1 M sodium citriate pH 6, 30 mM cupric sulfate, 5 mM potassium 
ferricyanate) for 4 hr at room temperature. The clot was rinsed with 50% methanol 
and then counter stained with Harris Haematoxylin (Sigma) for 1-5 min. After 
rinsing with water, it was stained by a weak ammonia solution for 1 min and finally 
washed in water for 3 times. An inverted-microscope was used to identify MK 
colony which was defined as cluster of three or more AChE-positive cells. 
3.1.2 Human colony-forming unit-megakaryocyte (CFU-MK) assay 
3.1.2.1 Cord blood collection and selection of CD34+ stem cells 
Umbilical cord blood was collected from normal, full-term vaginal deliveries in our 
labor ward. It was collected by syringes from the cord vein and stored in universal 
container (Sterilin; Staffordshire, United Kingdom) containing 2 ml preservative-free 
sodium heparin at 10 lU/ml (David Bull Laboratories; Victoria, Australia) 
supplemented with 100 lU/ml penicillin (Gibco) and 100 jiig/ml streptomycin 
(Gibco). Informed consents were obtained for all blood collection and the study was 
approved by the Ethics Committee for Clinical Research of the Chinese University of 
Hong Kong. 
Anticoagulated cord blood samples were diluted with an equal volume of IMDM and 
laid carefully on top of an equal volume of Ficoll-Paque (density 1.077) (Pharmacia; 
Uppsala, Sweden). The tube was centrifiiged at 400 g without brake at room 
temperature for 35 min. The mononuclear cells were collected after washing twice 
with Ca2+ and Mg'^ free phosphate buffered saline (PBS, pH7.4) (Gibco) 
supplemented with 0.6% anticoagulants citrate dextrose formula A (ACD) (Baxter; 
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Deerfield，IL, USA) and centrifugated at 200 g for 10 min at room temperature. 
Mononuclear cells were suspended in 1 ml PBS/0.6% ACD. 
The CD34 progenitor cell isolation kit (Miltenyi Biotec; Gladbach, Germany) was 
used for the isolation of hematopoietic progenitor cells by positive selection of CD34 
expressing cells using a hapten-conjugated primary monoclonal antibody and an anti-
hapten antibody coupled to MACS MicroBeads. The isolation kit contains a) 
Reagent Al, human Ig (FcR blocking reagent); b) Reagent A2, anti-human 
monoclonal hapten-conj ugated CD34 antibody (Clone QB END/10); c) Reagent B, 
colloidal super-paramagnetic MACS MicroBeads conjugated to an anti-hapten 
antibody. During CD34+ cell enrichment, Reagent Al (100 |il/lxlO^ cells) and 
reagent A2 (100 }il/lxlO^ cells) were added to cord blood mononuclear cells and 
incubated at 4°C for 15 min, with gentle shaking for every 5 min. Cells were washed 
with PBS/0.6% ACD and recovered by centrifugation at 200 g at room temperature 
for 10 min. The cell pellet was resuspended in PBS/0.6% ACD. Reagent B (100 jul/ 
1x108 cells) was then added to a total volume of 500 jul and incubated at 4°C for 15 
min, with gentle shaking for every 5 min. Cells were washed by PBS/0.6% ACD, 
centrifugated at 200 g for 10 min at room temperature and recovered in 1 ml 
PBS/0.6% ACD. 
The magnetic bead-labeled cells were selected using positive selection columns 
placed in the magnetic field of the MiniMACS instrument. The system contained a 
high gradient magnetic separation column for positive selection, flow resistor and 
plunger for elution of positively selected material. The column had a hydrophilic 
coating that allowed rapid filling and washed with 2 ml PBS/0.6% ACD before used. 
After applying magnetic labeled cells, the unbound cells were was washed by 1 ml 
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PBS/0.6% ACD. The column was removed from separator and placed on a suitable 
collection tube (Falcon, Becton Dickinson, BD; Franklin Lakes, NJ, USA). PBS at 
0.5 ml was applied on top of the column and the positively labeled cells were flushed 
out using the plunger. The procedure was repeated using a new column to increase 
purity of the positive cell fraction. 
The purity of the CD34+ fraction was assessed by flow cytometry after staining the 
cells (5x105) with 14 |LI1 each of either CD34 anti-HPCA-2-fluorescein isothiocyanate 
(FITC) and CDS 8 Leu™-17-phycoerythrin (PE) or 14 of the Stimultest™ control 
YiYi (Beckon Dickinson; San Jose, USA). CD34 antigen was a surface marker of total 
hematopoietic stem and progenitor cells; CD34+ CD38" cells were early or 
uncommitted stem and progenitor cells. The control y^ y^  antibody was used to detect 
nonspecific bindings. The cells were incubated for 20 min in the dark. The cells were 
washed with 2 ml PBS and centrifuged at 200 g for 6 min. The supernatant was 
discarded and cell pellet was resuspended in 0.5ml 1% paraformaldehyde (pH 7.4) 
(Sigma). CD34 and CD38 cell subsets were measured by FACScan cytometer and 
the Lysis II program (Becton Dickinson). For the analysis of CD34+ subsets, a total 
of 200,000 events were acquired and the CD34 negative cells were excluded by 
gating. 
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3.1.2.2 Treatment with IL-lp 
The effect of IL-1 (3 was compared with that of TPO, IL-3 and IL-6 on human CFU-
MK formation by the addition of 20 ng/ml of each cytokine to the culture (3x1 CP 
CD34+ cells). The concentrations of individual cytokines have been optimized in a 
previous pilot study (Li et al, 2000). All cytokines were purchased from PeproTech 
(London, England). 
3.1.2.3 Human CFU-MK culture 
Mononuclear cells from umbilical cord blood were separated by centrifugation using 
Ficoll-Paque (Density 1.077，Pharmacia) with two washes in IMDM. CD34+stem 
cells were enriched using immunomagnetic separation (Miltenyi Biotec). Enriched 
CD34+ cells at SxlOVml were added to the plasma-clot culture system (1% deionized 
bovine serum albumin, 0.34 g calcium chloride, 10% citrated bovine plasma, 100 U 
penicillin, 50 streptomycin) with IL-ip, TPO, IL-3 or IL-6 (20 ng/ml each). After 
incubation for 12 days, the colonies were examined under an inverted-microscope. 
The megakaryocytic colonies were further verified by an immunocytochemical 
method. The dishes were incubated with an anti-CD41 monoclonal antibody (Dako; 
Copenhagen, Denmark) for 30 min at room temperature. After washing with 
PBS/0.5% bovine serum albumin (BSA) (Sigma) for 3 times, cells were incubated 
with streptavidin, biotinylated alkaline phosphatase and substrates consisting of 
naphthol AS-MX phosphate-fast red (Dako). It was washed with PBS/0.5% BSA for 
3 times after each incubation. A CFU-MK colony was defined as a cluster of three or 
more MK cells detected under light microscopy. 
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3.1.3 Calculations of CFU-MK 
The number of CFU-MK was evaluated using the equation: 
(total nucleated cells/number of cells seeded) x number of colonies formed 
3.1.4 Effects of IL-1 p on the Meg-01 cell growth 
Meg-01 cells were incubated with or without IL-lp (PeproTech) at 20 ng/ml for 24 
or 48 hr. Cell counting was performed after each time-point. 
3.2 Detection of mRNA expressions of IL-1 receptors (IL-IRI and IL-IRII) 
in human megakaryocytic cell lines and primary cells 
3.2.1 Cell culture 
3.2.1.1 Human cell lines 
Meg-01, a megakaryoblastic cell line, was kindly provided by Dr H. Saito, Japan 
(Ogura et al, 1985). It was established from the bone marrow of a patient with 
Philadelphia (Ph^) chromosome-positive, chronic myelogenous leukemia at blast 
crisis. Megakaryoblastic cell lines CHRF-288-11 (CHRF), Dami, and the erythroid 
cell line K562 were obtained from American type culture collection (ATCC) 
(Rockville, USA). CHRF was established from a biopsy of a metastatic tumor in a 
17-month-old infant with acute megakaryoblastic leukemia. Dami was established 
from the blood of a patient with megakaryoblastic leukemia. K562 was established 
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from the blood of a patient with chronic myelogenous leukemia. These cells were 
cultured with IMDM (Gibco) containing 10% heat-inactivated fetal calf serum (FCS) 
(Gibco). M-07e, a cytokine-dependent human megakaryocytic cell line (ATCC) was 
cultured with IMDM containing 10% FCS and IL-3 (25 ng/ml). K562 cells were 
cultured in IMDM with 10% FCS as control cells of the erythroid lineage. All cells 
were maintained with penicillin G (100 U/ml) and streptomycin (50 |Lxg/ml) at 37°C 
in 5% CO2 and air in a humidified incubator. The total cell count and cell 
death/viability were performed before and after each experiment as mentioned in 
section 3.1.1.1. Viability greater than 90% was considered as acceptable before each 
treatment was performed. 
3.2.1.2 Ex vivo expansion of megakaryocytic progenitors from enriched CD34+ 
stem cells 
Enriched CD34+ cells (5x10' cells/ml) (MiniMACS) were expanded in IMDM, 
supplemented with 10% FCS, 20 ng/ml each of IL-3, IL-6, Flt-3L and TPO (50 
ng/ml). Three-quarter of expanded cells were split into 3 separate wells and 
expanded for further 7 days in fresh IMDM supplemented with FCS and cytokines. 
At day 14, expanded cells were washed with PBS and stained with 10 \il each of 
Platelet Glycoprotein Ilia, CD61/FITC and Platelet Glycoprotein lib, CD41/PE 
antibodies (Dako; Copenhagen, Denmark) to label the MK cells. After washing with 
PBS/0.5% BSA, the cells were centrifuged at 200 g at room temperature for 6 min 
and resuspended in 0.5 ml 1% paraformaldehyde (pH 7.4) (Sigma). The double 
positive cells were then purified by flow cytometry sorting and data acquisition was 
done by the Lysis II software package (FACStar plus, Beckon Dickinson; San Jose, 
USA). Calibration was done using calibration beads for better X- and Y-axis 
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alignment. For high purity, a rate around 2,500 events per second were applied. 
3.2.2 Reverse transcription-polymerase chain reaction (RT-PCR) and Southern 
blot analysis 
3.2.2.1 Extraction of total cellular ribonucleic acid (RNA) 
RNeasy Mini Kit (Qiagen; Hilden, Germany) was a specialized high salt buffer 
system which allowed the binding of up to 100 |Lig of RNA bound to the RNeasy 
silica-gel membrane. This protocol recruited mature cytoplasmic RNA where 
unspliced, partially spliced RNA, deoxyribonucleic acid (DNA) contamination 
should be minimized or nil. All procedures were performed at room temperature. The 
cells sorted with C D 6 l 7 4 r was harvested and washed by PBS (pH7.4). After 
centrifugation at 10,600 g for 10 min, the supernatant was removed completely. 
Incomplete removal of supernatant would inhibit cell lysis and affect the binding 
condition of RNA to the RNeasy membrane. For 5x10^ cells, Buffer RLT (with P-
mecaptoethanol added) at 350 |LI1 was added; for 1x10? cells, Buffer RLT at 600 \i\ 
was added to lyse the cells. Buffer RLT was a highly denaturating guanidine 
isothiocyanate (GITC)-containing lysis buffer which immediately inactivated RNases 
to ensure isolation of intact RNA. The cell lysate in Buffer RLT was used 
immediately or stored at —70°C for later use. The frozen lysate was thawed and 
incubated at 37�C for 10 min to ensure that all the salt has dissolved. The sample was 
then homogenized by passing the lysate through a 20-G needle fitted to a syringe for 
at least 10 times. Incomplete homogenization would result in loss of RNA. One 
volume (350 or 600 |il) of 70% ethanol was added to the homogenized lysate to 
perform ethanol precipitation, and the sample was mixed gently. Up to 700 \i\ of 
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sample was applied, including any precipitate which might have formed, to an 
RNeasy mini spin column sitting in a 2 ml collection tube. The tube was centrifuged 
for 2 min at 10,600 g and the flow-through was discarded. After that, Buffer RWl 
(wash buffer) at 700 juil was added onto the RNeasy column and it was centrifuged 
for 1 min at 10,600 g. The RNeasy column was then transferred into another 2 ml 
collection tube. Buffer RPE (with 4 parts of 100% ethanol added) at 500 jul was 
added onto the RNeasy column and it was centrifuged for 1 min at 10,600 g to wash 
and the flow-through was discarded. Then, another 500 |LI1 Buffer RPE was added 
and it was then centrifuged for 2 min at 20,800 g to dry the RNeasy membrane. The 
RNeasy column was then transferred to a new 1.5 ml collection tube and 30 pJ or 50 
pi RNase-free water was added directly onto the membrane. It was incubated for 3 
min to ensure that the membrane was wetted. To elute the RNA sample, it was 
centrifuged for 2 min at 10,600 g and was used immediately or stored at —20�C for 
later use. The RNA sample at 5 |LI1 was diluted to 70 |LI1 with diethyl pyrocarbonate 
double-deionized water (DEPC-ddHzO) (1:14 dilution) and the quality and quantity 
of RNA were measured by optical density measurement using the Gene Quant 
RNA/DNA calculator (Pharmacia; Uppsala, Sweden). 
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3.2.2.2 RT-PCR 
The first-strand complementary DNA was synthesized from total cellular RNA using 
the Superscript^^ II RNase H' Reverse Transcriptase (Gibco). Total cellular RNA at 1 
^g was reverse-transcribed in a final volume of 20 ]i\ reaction mixture containing 50 
mM tris-hydrochloric acid (Tris-HCl) (pH8.3)，75 mM potassium chloride (KCl), 3 
mM magnesium chloride (MgCy，1 mM dithiothreitol (DTT), 0.5 mM 2' 
deoxyadenosine 5'-triphosphate (dATP), 0.5 mM 2' deoxycytidine 5'-triphosphate 
(dCTP), 0.5 mM 2’ deoxy guano sine 5'-triphosphate (dGTP), 0.5 mM 2’ 
deoxythymidine 5'-triphosphate (dTTP), 50 ng random hexamer and 200 U 
Superscript™ II enzyme. The RT reactions were performed at 42°C for 1 hr, followed 
by inactivation of the enzyme at 70°C for 15 min. One to five dilutions of RT product 
were performed using DEPC-ddHsO. Subsequently, cDNA at 5 was amplified 
using 10 pmole of forward and reverse primers, 20 mM Tris-HCl (pH8.4), 50 mM 
KCl, 2 mM MgCl2, 0.2 mM of each deoxyribonucleoside triphosphate (dNTP) 
(Boehringer Mannheim; Mannheim, Germany), and 1.5 U Taq DNA polymerase 
(Gibco) in a final volume of 25 |LI1. The PCR reactions were performed in a Peltier 
Thermal Cycler PTC-200 (MJ Research; Watertown, USA). The reaction conditions 
for different genes were optimized with denaturation at 94°C for 3 min and a final 
elongation at 72°C for 10 min. Other procedures, primer and probe sequences were 
described as follows: 
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G e n e P r i m e r s and probes sequences Annealing Size Genebank 
condition Accession 
IL-1 (35，-AGC TTG GTG ATG TCT GGT CCA TAT-3, 94�C 1 min 4 0 8 b p M 1 5 8 4 D 
5 ,-GGA AGA CAC AAA TTG CAT GGT GAA-3 ’ 30 cycles 
5 ’-TGT ACC TGT CCT GCG TGT TG-3 ’ 
IL-IRI 5'-TGATGT TCG TCC CTG TCC TCT T - 3 ‘ ^ 54°C 30 s 35 cycles 558bp XM002686 
5 ,-CTT GTG GGT TTG TTT TCC TCT A-3, 
5'-TGG AGA ATG AGC CTA ACT TAT G-3 ‘ 
IL-IRII 5’-AGT TTC TGC CTT CAC CCT TCA G-3，60°C 30 s 12 cycles 5 5 2 b p U 7 4 6 4 9 
5'-TGT ACG AGT AAG TGA GTG GTC C-3 ’ 57°C 30 s 25 cycles 
5，-GGA CGG TGC TCT GTG GCT TCT G-3 ’ 
NF-E2 5，-ATC ATG TCC ATC ACC GAG CTG C-3 ’ ^ 6PC 30 s 26 cycles 3 3 6 b p L 2 4 1 2 2 
5'-TGG GTC TTC TTG GGG CTT AGG T-3’ 
5'-TTC CCA CTT CCT CCA CCA CCT T-3’ 
GATA-1 5'-TCC CCC TGC CTC CCT GTG-3， 60°C 30 s 25 cycles 306bp AF196971 
5'-TCA GTG GCC GGT TCA C-3’ 
5，-AGT GTC GTG GTG GTC GTC-3' 
c - J u n 5 ' - G C C TAC AGA TGA ACT CTT TCT GGC-3 ’ 66�C 1 min 5 2 ^ 1 0 4 1 1 1 ~ 
5'-CTG AAA CAT CGC ACT AGC CTT TGG-3 ’ 26 cycles 
5，-ACA AAG GCA TGA AGC TGT-3 ’ 
c-Fos 5'-GGA TAG CCT CTC TTA CTA CCA C - 3 ' ^ 60°C 20 s 30 cycles 2 8 0 b p K 0 0 6 5 0 
5'-TCC TGT CAT GGT CTT CAC AAC G-3’ 
5'-ATG CTG GAG AAG GAG TCT GCG G-3’ 
PDH 5'-TGC GCT GCA GGT GAC AGT TC-3 ’ 60°C 30 s 29 cycles 191bp NM000925 
5 ’-CAA AGC CCA TCT CTG ATA TGG G-3 ’ 
5 ’-TGG GGC ATA CAA GGT TAG TC-3 ’ 
TPO 5 ’ - CTG CTT CGT GAC TCC CAT GTC — 3 ’ 59�C 30 s 27 cycles 3 7 7 b p D 3 2 0 4 6 
5 ‘ - CGC ACC TTT CCT CGG AGC AG - 3 ’ 
5 ’ - TGC TGC CAT CAC TCC CTC CA - 3 ’ 
55 
MATERIALS AND ME TIIODS 
For each pair of primers, a cycle titration (22-40 cycles) using equal amounts of 
DNA template was performed to optimize the PCR condition. The amplification of 
pyruvate dehydrogenase (PDH) was used as a control of RNA quality. There were 
three negative controls for each PCR: 1) 5 |LI1 of DEPC-ddHaO 2) 0.5 |LI1 human 
genomic DNA and 4.5 ！il DEPC-ddH^O and 3) 0.5 [il RNA and 4.5 |LI1 DEPC-ddHsO. 
The primers used were selected to span exons and gave no signal from genomic 
DNA or reverse transcriptase reactions lacking the reverse transcriptase. For c-Jun 
and c-Fos, DNase I (Gibco) digestion on total cellular RNA samples was done 
according to manufacturer's instructions before performing RT-PCR. DNase I 
digestion was required for the c-Jun gene because it lacked any intron and any 
contamination by DNA would result in a false positive PCR product. Our prelimary 
analysis also demonstrated that the detection of mRNA expression of c-Fos was more 
efficient after DNase I digestion. Total cellular RNA at 1 fig was digested in a final 
volume of 10 jul reaction mixture containing 1 pi of lOX DNase I reaction buffer 
(200 mM Tris-HCl pH 8.4, 20 mM MgCl� and 500 mM KCl) and 1 i^l of DNase I, 
the amplification grade (1 U/pl). The reactions were performed at room temperature 
for 15 min, followed by inactivation of the enzyme at 65°C for 10 min with the 
addition of 1 of 25 mM ethylenediaminetetraacetic acid (EDTA). The RNA 
sample was ready for use in reverse transcription, prior to amplification. 
3.2.2.3 Gel electrophoresis and alkaline transfer of RT-PCR products 
DNA gel (1.5%) was prepared by placing 0.75 g agarose (Sigma) in 50 ml IX Tris-
acetate-EDTA (TAE) (40 mM Tris, 20 mM acetate, and 2 mM EDTA) and then 
microwaved for 1 min. Upon cooling, 0.5 |LI1 ethidium bromide (Sigma) was added 
into gel mix. The gel mix was poured and bubble-forming should be avoided. The 
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cooled gel was placed in a gel buffer tank with IX TAB and until the gel was 
completely covered. Appropriate amounts of samples (5:1 dilution to sample buffer) 
and (|)174 /Haelll marker (Gibco) were loaded onto the gel and electrophoresis was 
performed at 120 V for about 1 hr. After fractionation, the agarose gel was washed in 
denaturing solution containing 1.5 M sodium chloride (NaCl) and 0.5 M sodium 
hydroxide (NaOH) for 20 min at room temperature with shaking. The gel face was 
placed down on a flattened surface and the air pockets were filled with denaturing 
solution to ensure flattening of the gel surface. A marked pre-cut Hybond- N+ 
membrane (Amersham; Buckinghamshire, England) was wetted with denaturing 
solution and placed on top of the gel with the gel marking side up. Six 
chromatography papers (Whatman grade, Sigma; Saint Louis, USA) were wetted 
with denaturing solution and placed on the membrane. Appropriate amounts of paper 
towels were then placed. A weight was placed on top of the assembly until it was 
balanced. The system was allowed to stand for at least 5 hr or overnight. After 
transferring, the membrane was washed in a neutralizing solution (pH 7.4) containing 
0.5 M Tris-HCl and 1.5 M NaCl for 20 min at room temperature with constant 
shaking and then UV crosslinked (UV Stratalinker™ 1800, Stratagene; La Jolla, 
USA). 
3.2.2.4 Southern blot analysis and detection 
Oligolabeled probes, hybridization buffer, liquid block, wash buffers and detection 
reagents were prepared according to the manufacturer's instructions from the ECL 
nucleic acid labeling and detection system (Amersham). The membrane was 
prehybridized in 10 ml pre-warmed hybridization buffer at 42�C for 30 min, and then 
hybridized with 5-10 ng/ml specific oligolabeled probes at 42�C for 2 hr in a rolling 
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hybridization incubator (Robbins Scientific Model 400, Robbins Scientific 
Corporation; Sunnyvale, USA). After hybridization, the membranes were washed 
twice with 5X saline sodium citrate buffer (SSC) containing 0.1% (w/v) sodium 
dodecyl sulfate (SDS) for 5 min at room temperature, then washed again twice with 
pre-warmed IX SSC containing 0.1% SDS for 15 min at 42�C. Membrane was then 
rinsed with buffer 1 (1 1 ddH^O with 8.766 g NaCl, 12.114 g trizma base, pH 7.5) for 
1 min and blocked with 0.5 ml liquid block in 9.5 ml buffer 1 for 30 min. After 
blocking, the membranes were incubated with the diluted (1:2000) anti-fluorescein 
horseradish peroxidase conjugate in 0.5 ml 10% BSA and 9.5 ml buffer 2 (1 1 ddHsO 
with 23.376 g NaCl, 12.114 g trizma base, pH 7.5) for 30 min at room temperature. 
The membrane was then washed with buffer 2 for 5 min and repeated for 3 times. 
The buffer was removed and the excess was drained from the washed blot which was 
then placed on a clean container, with the DNA side up. An equal volume of 
detection reagents (ECL nucleic acid detection system, Amersham) was prepared. It 
was then poured directly to the blot on the DNA side and incubated for 1 min at room 
temperature. The excess detection buffer was drained off and the blot was wrapped in 
transparency. Air pockets were gently smoothed out by kimwipes. The blot with the 
DNA side up was placed in the film cassette and subsequently developed by 
autoradiography using Hyperfilm™MP (Amersham). The intensities of bands on 
autoradiographs were scanned by an Imaging Densitometer (Bio-Rad; Hertfordshire, 
England) and analyzed by the Molecular Analyst™ software version 1.3 (Bio-Rad). 
Results were expressed as the ratio of the intensity of the gene band to PDH band 
obtained from the same sample. 
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3.3 Detection of protein expressions of IL-1 receptors (IL-IRI and IL-IRII) 
in human megakaryocytic cell lines and primary cells 
3.3.1 Flow cytometry detection 
The cultured cells were washed twice with PBS/0.1 % bovine serum albumin (BSA) 
(GIBCO) and 100 of cell suspension (5x10^ cells) were incubated with the 
appropriate antibodies or isotype controls. For detection of IL-IRI, biotin-conjugated 
rat anti-human CD 12la antibody (20 |ag/ml) (Pharmingen; San Diego, USA) was 
added to the cells for 30 min at room temperature in the dark. After washing for three 
times with PBS/0.1% BSA, the secondary streptavidin-FITC anti-rat antibody (25 
|ig/ml) (Pharmingen) was added and the reaction mixture was further incubated for 
30 min in the dark. After washing for three times with PBS/0.1% BSA, the cells were 
stained with CD41-PE (DAKO) for 20 min. Two antibodies, the IgG2a-FITC 
(Pharmingen) and the secondary streptavidin-FITC, were used as controls. For the 
detection of IL-IRII expression, the cells were stained with rat anti-human CD 12lb 
antibody (20 |Lig/ml) (Serotec; Oxford, England) and the secondary anti-rat IgG-
conjugated with PE before labeled with CD61-FITC (DAKO). The rat anti-human 
isotype IgG2a-PE antibody (Serotec) and the secondary IgG-PE were used as 
controls. Thirty thousand events were acquired for each cell line and 70,000 events 
were acquired for primary cell sample using a FACScan cytometer and the Lysis II 
program (Becton Dickinson). 
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3.3.2 Immunofluorescence staining of human bone marrow megakaryocytic cells 
3.3.2.1 Primary megakaryocytic cells from human bone marrow 
Bone marrow samples were obtained from normal marrow transplant donors. 
Informed consents were obtained for all blood collection and the study was 
approved by the Ethics Committee for Clinical Research of the Chinese University 
of Hong Kong. Mononuclear cells from human bone marrow samples were selected 
using Ficoll-Paque as described in section 3.1.2.1. 
3.3.2.2 Immunofluorescence staining 
The mononucleated cells were washed twice with PBS/0.1% BSA/0.6% ACD and all 
the staining procedures and materials were described in section 3.3.1, except that 
cells were re-suspended and washed in PBS/0.1% BSA/0.6% ACD. Microscope 
slides were washed by 100% ethanol and placed inside the cytospin instrument 
(Shandon; England). After getting balanced, sample with 1x10^ cells per 100 jiil was 
centrifuged at 80 g for 6 min. They were then fixed with absolute methanol/acetone 
1:1 (v/v), stored under anti-fade mountant solution (90% glycerol, 50 mM trizma 
base pH 8.0, 25 mg/ml propylgallate) at 4�C. The slides were examined under a 
fluorescent microscope (LEITZ; Germany). 
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3.4 Effects of IL-1 p on the expressions of c-Jun, c-Fos, GATA-1 and NF-E2 
in human megakaryocytic cell lines 
3.4.1 Dose-dependency effect of IL-1 p on the expression of transcription factors 
Meg-01 cells were starved overnight in 1% FCS in 5 ml IMDM. These cells (2x10^ 
cell/5 ml) were treated with IL-1 (3 for 1 hr at a dose of 0, 5, 15, 20, 25, 40, or 50 
ng/ml. The cells were PBS-washed and harvested for total protein extraction. 
3.4.2 Time-course effect of IL-1 p on the expression of transcription factors 
Meg-01 and CHRF cells were cultured at 1% FCS in 5 ml IMDM overnight. IL-ip 
was added to the culture medium at a dose of 25 ng/ml for 0, 15, 30, 60, 120 or 240 
min. For each set of experiments, two-third of the cells were harvested for total or 
nuclear protein extraction and the remaining for RNA extraction. 
3.4.3 mRNA expressions of transcription factors after IL-1 p treatment 
The procedures for the extraction of total cellular RNA, RT-PCR, gel electrophoresis 
and alkaline transfer of RT-PCR products, and Southern blot analysis and detection 
were described in section 3.2.2. 
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3.4.4 Protein expressions of transcription factors after IL-lp treatment 
3.4.4.1 Preparation of total protein extract 
Total cell lysates were prepared by adding 300 |LI1 lysis buffer to PBS-washed cell 
pellets (2x10)7 cells). The lysis buffer consisted of 20 mM N-[2-Hydroxyethyl: 
piperazine-N'-[2-ethanesulfonic] acid (HEPES) pH 7.4, 20 mM ethylene glycol-
bis[p-aminoethyl ether] (EGTA), 50 mM p-glycerophosphate, 1% trition X-100, 10% 
glycerol, 1 mM DTT and IX protease inhibitor (Protease Inhibitor Cocktail Tablets, 
Boehringer Mannheim). The cell suspension was incubated at 4�C for 30 min and 
mixed gently every 5 min. The cell suspension was then disrupted by sonication 
using the Soniprep 150 instrument (MSE Scientific Instruments; Sussex, England) at 
power 5 for 20 sec. It was then centrifuged for 10 min at 4°C at 17,900 g. The 
supernatant was recovered and frozen at -70°C. The protein concentrations were 
determined by the DC Protein Assay (Bio-Rad). 
3.4.4.2 Preparation of nuclear protein extract 
Nuclear cell lysates were prepared by adding 1 ml lysis buffer A to PBS-washed cell 
pellets (1x10' cells). The lysis buffer A consisted of 10 mM HEPES pH 7.9, 10 mM 
KCl, 1.5 mM MgCl2, 0.5 mM DTT, 0.5 mM phenylmethylsulfonyl fluoride (PMSF) 
(Sigma) and IX protease inhibitor (Protease Inhibitor Cocktail Tablets, Boehringer 
Mannheim). The cell suspensions were incubated at 4�C for 30 min and 40 |il of 20% 
Nonidet-P40 (NP-40) were added to the mixture. It was then centrifuged at 4�C for 
20 sec at 17,900 g. The cell pellet was resuspended in 1 ml lysis buffer A, and then 
centrifuged at 4�C for 20 sec at 17,900 g. Cell pellet was resuspended in 200 |LI1 lysis 
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buffer C and further homogenized by passing the lysate through a 20-G needle fitted 
to a syringe for at least 10 times. The lysis buffer C contained 20 mM HEPES pH 7.9, 
25% glycerol, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 0.5 mM DTT, 0.5 mM 
PMSF and IX protease inhibitor. The cell suspension was sonicated on ice using 
Soniprep 150 (MSE scientific instruments) at power 5 for 20 sec and then 
centrifuged for 10 min at 17,900 g at 4°C. The resulting supernatant (nuclear extract) 
was frozen at —70�C. The protein concentrations were determined by the DC Protein 
Assay (Bio-Rad). 
3.4.4.3 Measurement of protein concentration 
The protein standard curve was performed using stock 2 mg/ml BSA (Sigma). 
Standard (ng/ml) 0 2 5 0 500 750 1000 1250 1500 1750 2000 
BSA (2 mg/ml) 12.5^1 25^1 37.5^1 50 \x\ 62.5^1 7 5 ^ 1 8 7 . 5 i^l 100 i^l 
ddH^O 100 87.5 75 |il 62.5^1 50^1 37.5 |il 2 5 ^ 1 U J ^ A 
Appropriate dilutions were made for each sample to ensure that the absorbance of the 
sample was within the protein standard curve. Each protein standard and sample at 5 
|LI1 was added in duplicate to a 96-well-microplate. Reagent A (25 jil) and reagent B 
(200 were added to each standard and sample. The microplate was gently agitated 
and the absorbance (650 nm-750 run) was measured by the Dynatech MRS000 
microplate reader (Dynatech Laboratories; Chantilly, VA, USA). 
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3.4.4.4 Preparation of Sodium dodecyl sulfate- polyacrylamide gel electrophoresis 
(SDS-PAGE) 
All the accessories of the Mini Protean II Electrophoresis Cell (Bio-rad) were 
cleaned with 100% ethanol and kimwipes before use. Gel and stacker mix were 
prepared as follows: 
" " " Gel Mix (10%) I Stacker Mix (4%) 
d M f i 4.85 ml 3.17 ml 
1.5 M Tris-HCl pH 8.8 1.25 ml 
10% SDS 100 111 
(1:19) 40% Acrylamide/bis (Sigma) i J m l OTml 
10% Ammonium persulfate (APS) 50 jul 25 jiil 
N，N,N, ’N, -tetramethyl-ethylenediamine (TEMED) ^ 
Total Volume 10 ml 5 ml 
Stock (1:19) 40% acrylamide/bis was prepared inside famehood. APS at 10% and 
TEMED were added before use. The gel mix was poured gently to avoid bubble 
formation. A layer of ddHzO was carefully overlaid on the gel solution slowly and to 
avoid diluting the gel mix. The gel was allowed to polymerize for 1 hr on a flat 
surface and then the overlaid water was removed with paper towel and needle fitted 
into a syringe. The stacker mix was next poured and a comb was placed in the gel 
sandwich with all teeth covered by the solution. The stacker was allowed to 
polymerize for 1 hr. After setting, the gel was placed into the buffer chamber and the 
comb was removed. The solution inside each well was removed by a needle fitted 
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into a syringe. 
3.4.4.5 Gel electrophoresis and membrane transfer 
The sample (40-60 |Lig whole cell lysate or 10-20 |Lig nuclear extract) was mixed with 
an equal volume of 2X electrophoresis sample buffer (0.75 M Tris-HCl pH 8.8, 4% 
SDS, 20% glycerol, 1.25% 2-mercaptoethanol and 0.5% bromophenol blue) and 
boiled for 5 min at 95°C. Cruz Marker^^ molecular weight standards (1.6 }ag，Santa 
Cruz Biotechnology Inc., Santa Cruz, U.S.A.) at 1 |il and 10 )LI1 of samples were 
loaded onto the 10% acrylamide/bis-acrylamide (19:1, Sigma) gel. Equal amounts of 
sample buffer were loaded into empty wells and the buffer chamber was refilled with 
tris-glycine mmiing buffer (0.05 M Tris-HCl, 0.038 M glycine and 1% SDS, pH 8.3). 
The gel was then electrophoresed at 120 V for 110 min using the PowerPac 300 (Bio-
rad). 
After electrophoresis, the gel was marked at the marker side and rinsed by cooled 
(4°C) IX transfer buffer (0.05 M Tris-HCl and 0.038 M glycine). The PVDF 
membrane (Hybond-P, Amersham) was then pre-wet with absolute methanol and 
rinsed with cooled IX transfer buffer. The pre-wetted PVDF membrane was placed 
on top of the rinsed gel and sandwiched between pre-wetted mini trans-blot fiber 
pads and pre-wetted chromatography papers (Whatman grade, Sigma). A small stir 
bar, the transfer cells and ice box were placed in the electroblotting apparatus. Pre-
cooled IX transfer buffer was added to cover the transfer cells. It was run at 230 mA 
for at least 2 hr using the PowerPac 300 (Bio-Rad). 
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3.4.4.6 Western blotting and detection 
After blocking overnight at 4°C in freshly prepared 5% non-fat milk (Carnation, 
Nestle; CA, USA) and washing with Tris buffered saline (TBS), the membranes were 
incubated with respective antibodies (Santa Cruz) overnight at 4°C. The membrane 
was then washed with TBS-0.5% Tween 20 for 10 min at room temperature for 6 
times, 8 min for 2 times, and then washed with TBS for 5 min once. Then it was 
incubated with respective horseradish peroxidase-conjugated IgG antibodies for 2 hr 
at room temperature. After incubation, the membrane was washed with TBS-0.5% 
Tween 20 for 10 min for 6 times and then washed with TBS for 5 min one time. 
The buffer was removed and the excess buffer was drained from the washed blot 
which was then placed on a container, with the protein side up. An equal volume of 
1:1 diluted detection reagent (ECL western blotting detection system, Amersham) 
were prepared and mixed before used. It was then poured directly to the blot on the 
protein side and incubated for 1 min at room temperature. The excess detection 
buffer was drained off and the blot was wrapped in a transparency film. Air pockets 
were gently smoothed out by kimwipes. The blot protein was subsequently 
developed by autoradiography using Hyperfilm丁"MP (Amersham). The intensities of 
bands on autoradiographs were scanned by an Imaging Densitometer (Bio-Rad; 
Hertfordshire, England) and analyzed by the Molecular Analyst™ software version 
1.3 (Bio-Rad). Results were expressed as the ratio of the intensity of the sample band 
to actin band obtained from the same sample. 
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The details of the antibodies used were described as follows: 
Primary Cat. No. Notes Respective 2"'' Molecular Weight Dilution 
Antibody antibody 
c-Jun/AP-1 (N) sc-45 N-terminal domain of Anti-rabbit 39 kDa ^ 1:1000 
mouse c-Jun p39 
c-Fos (H-125) sc-7202 Amino acids 210-335 Anti-rabbit 62 kDa 1:1000 
mapping at the C-terminal 
of c-Fos of human origin 
NF-E2 ( C - 1 9 ) s c ^ C - t e r m i n a l of NF-E2 of Anti-rabbit 45 kDa 1:500 
mouse origin 
GATA-1 ( N l ) s ^ ^ = Anti-rat 47 kDa 1:500 
~ A c t i n (C2) sc-8432 C-terminal ofactinof Anti-mouse 43 kDa 1:1000 
human origin 
Secondary Cat. No. Notes Dilution 
Antibody 
Anti-rabbit sc-2030 Horseradish-Peroxidase conjugated 1:1000 
IgG-HRP 
Anti-mouse sc-2031 Horseradish-Peroxidase conjugated 1:1000 
IgG-HRP 
Anti-rat sc-2032 Horseradish-Peroxidase conjugated 1:1000 
IgG-HRP 
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3.5 Mechanism of activation of the signal transduction pathway by IL-1 p 
in human megakaryocytic cell line CHRF-288-11 
3.5.1 Effects of IL-1 receptor antagonist (IL-IRA) on the nuclear accumulations 
of c-Jun, c-Fos, NF-E2 and GATA-1 induced by IL-ip 
To test the interaction of IL-1 p with its functional receptor, CHRF cells were treated 
with IL-IRA (R&D systems; Minneapolis, USA). IL-IRA competed with IL-lp for 
receptor binding, but did not interact with it. It bound to both types of IL-1 receptors 
(I and II). IL-IRA at 10 jag was dissolved in filtered 0.1% BSA/PBS and stored at — 
20�C, with a working concentration of 1 ng/jjl CHRF cells (2x10?) were starved 
overnight in 1% FCS in 5 ml IMDM in the presence of IL-IRA (0, 125, 250 or 500 
ng/ml). Treated cells were then exposed to 25 ng/ml of IL-ip for 1 hr prior to 
harvesting for nuclear protein extraction and RNA extraction. The treatment with IL-
IRA (500 ng/ml) alone was also included in the study. 
3.5.2 Effects of TPO neutralizing antibody (TPO Ab) on the nuclear 
accumulations of c-Jun, c-Fos, NF-E2 and GATA-1 induced by IL-ip 
This antibody has been selected for its ability to neutralize the biological activity of 
recombinant human TPO (rhTPO). The neutralization dosCso (ND50) for this antibody 
was approximately 5-10 \ig/ml in the presence of 10 ng/ml of rhTPO as determined 
by the manufacturer. Anti human TPO antibody powder (R&D systems) and isotype 
control IgG antibody powder (R&D systems) were dissolved in filtered PBS (pH 7.4) 
to provide the working concentration of 1 |Lig/|al and stored at —20�C in aliquots. 
These samples would be stable for 6 months without detectable loss of activity as 
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recommended by the manufacturer. After overnight starvation in 1% FCS in 5 ml 
IMDM, CHRF cells (2xl0') were pretreated with TPO Ab (0, 5, 10 or 15 [ig/m\) for 
2 hr before exposure to IL-ip for 1 hr. Another two independent experiments were 
performed for investigating the effects of TPO Ab on the expression of c-Jun and c-
Fos. CHRF cells were treated with the same protocol, except the exposure time to IL-
ip was 30 min, instead of 1 hr. Pretreated cells were exposed to 25 ng/ml of IL-1 (3 
for an additional 1 hr prior to harvesting for nuclear protein and RNA extraction. 
Treatments with isotype control IgG antibody (Iso Ab), TPO neutralizing antibody 
alone (15 lag/ml), recombinant TPO alone (15 ng/ml) and recombinant human TPO 
(15 ng/ml) + TPO neutralizing antibody (15 jug/ml) were also performed as controls. 
3.5.3 Effects of actinomycin D (ActD) and cycloheximide (CHX) on the nuclear 
accumulations of c-Jun, c-Fos, NF-E2 and GATA-1 induced by IL-ip 
CHRF cells were pretreated with ActD (sigma) and CHX (Supelco; West Chester, 
USA) to investigate the mechanism of the inductive of IL-ip on the various 
transcription factors. ActD and CHX were dissolved in filtered 100% ethanol (EtOH) 
to provide the working concentration of 0.2 |ag/|Lil and 50 ng/|Lil respectively, and 
stored at —20°C in the dark. After overnight starvation in 1% FCS, CHRF cells (2xl0') 
were pretreated with ActD (0, 5，10, 50, 100 or 500 ng/ml) or CHX (0, 0.1, 0.5, 1 or 
2 fag/ml) for 2 hr before exposure to IL-1 (3 for 1 hr. All cultures contained 1% EtOH. 
Pretreated cells were then exposed to 25 ng/ml of IL-1 p for an additional 1 hr prior 
to harvesting for nuclear protein and RNA extraction. Treatment with EtOH (1%), 
ActD (500 ng/ml) or CHX (2 |ag/ml) alone were included as controls. 
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3.6 Statistical Anslysis 
The comparison between cytokine treatments on CFU-MK formation was analysed 
by the Kruskal-Wallis One way Analysis of variance (ANOVA) and the Student-
Newman-Keuls test using the SigmaStat 2.0 software. A p-value of 0.05 or less was 
considered to be statistically significant. All data were expressed as mean 土 standard 
error of mean (S.E.M.). 
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RESULTS AND DISCUSSION 
EFFECT OF IL-ip ON MEGAKARYOCYTIC CELLS AND 
IDENTIFICATION OF IL-IRI AND RII ON HUMAN 
MEGAKARYOCYTIC CELL LINES AND PRIMARY 
MEGAKARYOCYTES 
4.1 Effects of IL-lp on the growth and development of megakaryocytic 
progenitors 
4.1.1 Murine CFU-MK 
In four independent and duplicate experiments, IL-ip stimulated murine CFU-MK 
formation in a dose-dependent manner with an optimal dose at 20 ng/ml (p = 0.004 at 
20 ng/ml) (Figure 4.1). TPO at 20 ng/ml stimulated CFU-MK formulation and its 
effect was slightly enhanced by IL-ip (n = 4, p = 0.05) (Figure 4.1). 
In four independent and duplicate experiments, the addition of TPO, IL-1, IL-3, and 
IL-6 at 20 ng/ml significantly stimulated murine CFU-MK formation (p : 0.001). 
The mitogenic effect of IL-1 (3 was less than that of TPO (p = 0.05), but stronger than 
that of IL-3 and IL-6 (p = 0.05) (Figure 4.2). 
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Furthermore, in three independent experiments (ANOVA p = 0.002), IL-lp 
significantly stimulated TPO-mediated murine CFU-MK formation (56 士 11 
colonies/2xl0' cells vs. 35 ± 8 colonies/2xl0^ cells, p = 0.018). While all the 
cytokines significantly activated murine CFU-MK formation when compared with 
the control (p = 0.05), only IL-lp enhanced the effect of TPO in this culture system 
(Figure 4.3). 
4.1.2 Human CFU-MK 
In three independent experiments, effects of TPO, IL-ip, IL-3 and IL-6 were 
investigated, starting with enriched CD34+ cells of cord blood (Purity range 86% -
96%). IL-ip significantly promoted human CFU-MK formation when compared 
with the control group (14 土 4 colonies/3xlO^ cells vs. 4 ± 2 colonies/3x 10^  cells, p = 
0.0108). While all the cytokines significantly increased human CFU-MK formation 
when compared with the control (p = 0.05), there was no significant difference 
between those treatments with IL-ip, IL-3 and IL-6. Treatment with TPO resulted in 
the highest yield of human CFU-MK when compared with IL-3 and IL-6 (p = 0.05) 
(Figure 4.4). 
4.1.3 Effects of IL-lp on the Meg-01 cell growth 
In four independent experiments, IL-lp (20 ng/ml) significantly stimulated Meg-01 
cell growth when incubated with IL-1 (3 for 24 hr (1.35 士 0.25 x 10^  cells/ml, p = 0.05) 
and 48 hr (1.90 土 0.5 x 10^  cells/ml, p = 0.01) when compared with the control group 
without the cytokine (1.14 土 0.4 x 10' cells/ml). 
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4.2 Detection of mRNA expressions of IL-1 receptors (IL-IRI and IL-IRII) 
in human megakaryocytic cell lines and primary cells 
By RT-PCR analysis, IL-1 (3 mRNA was detected in MK cell lines Meg-01, Dami, 
CHRP and M-07e, but not in erythroid cell line K562. The PGR product had the 
expected molecular size of 408 bp as determined by (|)174/HaeIII markers (Figure 
4.5). 
IL-IRI mRNA RT-PCR products (558 bp) were demonstrated in Meg-01, Dami, 
CHRF and, very weakly, in M-07e. K562 cells also expressed the type I receptor 
(Figure 4.5). IL-IRII mRNA was detected in Meg-01, Dami and CHRF, but not in 
M-07e. A very faint band was observed with K562 cells only after Southern 
hybridization (Figure 4.5). There were two distinct RT-PCR products of IL-IRII of 
552 bp and around 400 bp. By sequence analysis, the smaller band represented a 
product of IL-IRII with a loss of 160 bp on exon 3. 
Transcription factor NF-E2 (336 bp) was expressed in all four MK cell lines and the 
erythroid cell line K562 (Figure 4.5). 
The expressions of these genes were confirmed by Southern hybridization. As a 
control of RNA quality, amplification of PDH (191 bp) was performed (Figure 4.5). 
All primers gave no signal from genomic DNA or reverse transcription reactions 
lacking the reverse transcriptase. Cycle titrations were prior performed to optimize 
the PCR condition of all primers (data not shown). 
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Our established protocol of expansion of enriched CD34+ cells from cord blood 
produced over 10% of CD6V CD41+ cells after 14 days of culture (Li et al, 2000). 
After FACS sorting of five samples from two independent expansions, the purity of 
CD6V CD41+ cells was 93.4% 士 2.09o/o (range 86-98%) (Figure 4.6). RT-PCR 
reactions were performed on individual samples. Expressions of IL-1 p (408 bp), IL-
IRI (558 bp), IL-IRII (552 bp) and NF-E2 (336 bp) mRNA were detected in all the 
samples (Figure 4.5). 
4.3 Detection of protein expressions of IL-1 receptors (IL-IRI and IL-IRII) 
in human megakaryocytic cell lines and primary cells 
4.3.1 Flow cytometry detection 
The surface expression of IL-IRII was demonstrated in Meg-01, Dami and CHRF, 
but not in M-07e or K562 (Figure 4.7). Very slight expression of IL-IRI was detected 
on Meg-01, but not in other cell lines (data not shown). 
The expression of IL-IRI receptors was determined in three independent expansion 
cultures and MK cells were marked by the CD41 antibody. Expressions of IL-IRI 
(CD 121 a-FITC/CD41 -PE) were 1.26%, 1.50%, 1.46% of total cells and 46.1%, 
27.5%, 32.4% of CD41 positively stained cells respectively (Figure 4.8, upper-panel). 
IL-IRII receptors were studied in two independent expansions and MK cells were 
stained by the CD61 antibody. Expressions of IL-IRII (CD 121 b-PE/CD61 -FITC) 
were 0.10%, 0.14% of total cells and 1.05%, 0.83% of CD61 positively stained cells 
respectively (Figure 4.8, lower-panel). 
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4.3.2 Immunofluorescence staining 
IL-IRJ receptors (CD121a-FITC) were detected in bone marrow MK cells as marked 
by CD41-PE staining. A population of MK cells that were CD61-FITC positive also 
expressed IL-IRII as stained by CD121b-PE (Figure 4.9). 
It appeared that the MK progenitors, which were smaller in size, expressed higher 
levels of IL-1 RI and RII receptors when compared with the larger, mature MK cells. 
However, we could not rule out the possibility that the strong fluorescent expression 
of CD41 and CD61 antibodies on the mature cells masked the weak staining of the 
receptors. Bone marrow MK cells were not positively stained with the isotypic 
control antibodies (data not shown). 
4.4 Discussion 
The stimulating effects of IL-lp, in combination with other cytokines, on pluripotent 
stem cells and the myeloid lineage have been well established (Fibbe et al, 1988; 
Kobayashi et al, 1991; Brugger et al, 1993). In previous reports, the association 
between IL-ip and the MK lineage has been essentially considered as indirect. IL-1 (3 
alone induced and protected megakaryocytopoiesis in animal models (Nakai and 
Hirai, 1989). The actions were suggested to be mediated by cytokines induced from 
accessory cells such as macrophages, lymphocytes or stromal cells. 
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In the present study, we demonstrated that IL-lp supported the formation of CFU-
MK from murine bone marrow and human CD34+ - enriched cells obtained from 
cord blood. These results were in line with those reported recently that IL-1 (3 was an 
important cytokine for the ex vivo expansion of CD34+ to C D 4 r cells (Williams et al, 
1998; van den Oudenrijn et al, 1999). The latter group demonstrated that IL-ip 
significantly enhanced the effect of MK growth and development factor on the 
expansion of MK progenitors whereas stem-cell factor (SCF), IL-6 and IL-11 did not 
exert a large effect. In a recent report, the combination of TPO and IL-1 was regarded 
as the most effective in producing high numbers of both immature and mature MK 
cells in cultures of peripheral blood stem cells for transplant purpose (van den 
Oudenrijn et al, 2000). 
The role of IL-ip on the MK lineage was further strengthened by the identification 
of IL-IRI and RII expressions on MK cell lines and primary cells. Two known IL-1 
receptors (IL-IRI, 80 kDa and IL-IRII, 68 kDa) and one receptor accessory protein 
(IL-lRAcP) have been identified in many cell types. In the hematopoietic 
environment, IL-IRI expression was reported on T cells, fibroblasts, endothelial cells 
and the IL-IRII was demonstrated on B cells, granulocytes and macrophages 
(Dinarello, 1991; 1996). However, the expression of IL-1 receptors has not been 
reported in the MK lineage. In this study, the expression of IL-1 receptors on MK 
cells was confirmed by several methods, including RT-PCR, Southern blot analysis 
of mRNA expression, flow cytometry and immunofluorescence staining. The latter 
two methods demonstrated that the two receptors were expressed in a subpopulation 
of primary CD41 or CD61 positively stained cells. The expression of IL-1 receptor 
might be under developmental control, being up-regulated at the early progenitor 
cells. However, we were not been able to confirm such possibility because specific 
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differentiation and maturation markers for the MK lineage have not been available. 
The RT-PCR procedure had high sensitivity. However we could not rule out the 
possibility of a false positive result due to the presence of some minor 
contaminations of non-MK cells. From our results, there were two distinct RT-PCR 
products of IL-1 RII. By sequence analysis, it was caused by a loss of 160 bp on exon 
3. We did not determine whether this was the result of some PCR artifact or there 
was alternative splicing of the IL-1 RII mRNA. Flow cytometry was a quantitative 
method and could distinguish between MK and non-MK cells by simultaneous 
staining with multi-color antibodies. In addition, the immunofluorescence staining 
confirmed our findings by morphology, showing that IL-1 receptors protein was 
expressed on primary MK cells. 
In spite of the positive expression of IL-IRI mRNA in all four cell lines, we could 
not detect the IL-IRI antigen on three of the four cell lines by flow cytometry, 
possibly owing to the low expression of this receptor on these cells. The number of 
IL-IRJ molecules expressed in primary cells has been known to be very low (less 
than 200 per cell) and IL-1 signal transduction has been observed in cells expressing 
ten IL-IRI per cell (Dinarello, 1996). The present study was the first report on the 
identification of IL-IRI and RII receptors on MK lineage. The findings that all four 
MK cell lines and cultured cord blood MK cells expressed IL-lp mRNA were in 
agreement with those reported in human bone marrow MK cells (Jiang et al’ 1994)， 
MK cell lines HU3, MB02 (Sandrock et al, 1996) and CHRF (Soslau et al, 1997). 
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In summary, we demonstrated for the first time the expression of IL-1 receptors on 
MK cell lines and primary MK cells and the stimulating effect of IL-1 p on CFU-MK 
formation. Together with the expressions of IL-1 p in MK cells, IL-lp might exert its 
action on this lineage via an autocrine or paracrine mechanism. The expression of IL-
1 receptors was a strong evidence for the direct effect of IL-lp in the MK lineage. 
We attempted to confirm the expression of functional IL-1 (3 in the MK lineage in the 
following chapters. 
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Figure 4.1 - CFU-MK of murine bone marrow nucleated 
cells in response to IL-1 p. 
IL-ip at 0-50 ng/ml was added to the plasma clot cultures for 7 
days. IL-lp stimulated CFU-MK formation in a dose-dependent 
manner, (n = 4，p 二 0.004 at 20 ng/ml) (Mean 士 S.E.M.) 
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Figure 4.2 - Effects of IL-1(3, TPO, IL-3 and IL-6 on 
CFU-MK of murine bone marrow nuclea ted cel ls . 
At 20 ng/ml, the mitogenic effect of IL-1 (3 on CFU-MK 
formation was less than that of TPO (p 二 0.05), but stronger 
than that of IL-3 (p = 0.05) and IL-6 (p = 0.05). (n = 4) 
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Figure 4 .3 — E f f e c t s of IL-1(3, IL-3 , IL-6 , F l t -3L or S C F on T P O -
m e d i a t e d C F U - M K o f m u r i n e b o n e m a r r o w n u c l e a t e d c e l l s . 
At 20 n g / m l , IL-1 (3 s i g n i f i c a n t l y e n h a n c e d the e f f e c t o f T P O on 
CFU-MK formation, (n = 3, p = 0.018) 
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Figure 4.4 — Effects of IL-lp, TPO, IL-3, IL-6 on CFU-MK 
of h u m a n CD34+ e n r i c h e d c e l l s f r o m c o r d b l o o d . 
At 20 ng/ml, the added all cytokines significantly stimulated 
CFU-MK f o r m a t i o n (n = 3, p = 0 .05) when compared 
with the cont ro l cu l tu re . No d i f f e r e n c e was obse rved 
between the cytokines treatment of IL-1 (3, IL-3 and IL-6. 
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Figure 4.5 - Southern blot analysis of the expression of IL-1 (3, 
IL-IRI, IL-IRII, NF-E2 p45 and PDH in megakaryocytic cells. 
Lane 1，primary megakaryocytic cells (CD61+ CD41+) 
enriched by FACS sorting of expanded cord blood 
CD34+ cells to 95% purity. Lane 2，Meg-01. Lane 3, Dami. Lane 4, CHRF. Lane 5, M-07e. Lane 6, K562. Lane 7, 
negative control of PCR. Lane 8, genomic DNA control. 
Lane 9, negative control without reverse transcriptase. 
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Figure 4.6 - Representative diagrams of cell sorting profile. 
(A) Quadrant R1 was drawn to exclude cell debris . 
(B) CD61-FITC and CD41-PE double-pos i t ive cells 
(upper-right quadrant) were sorted to a purity of 95.5%. 
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Figure 4.7 - Identification of IL-1 type II receptor 
on megakaryocytic cell l ines by f low cytometry. 
IL-1 type II receptors (solid histograms) were detected in 
Meg-01, Dami and CHRF, but not in M-07e and K562 
when compared with isotype controls (open histograms). 
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Figure 4.8 — Identification of IL-1 type I and II receptors on 
expanded cord blood megakaryocytic cells by flow cytometry. 
Enriched CD34+ cells were cultured for 14 days in the presence 
of Flt-3L, TPO, IL-3 and IL-6. IL-1 RI and RII expression on 
megakaryocytic cells were detected by dual-labeling with 
CD121a-FITC/CD41-PE (top right) and CD61-FITC/CD121b-PE 
(bottom right) respect ively. The cells stained with the 
respectively isotype control antibodies (IG, top left and bottom left) 
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Figure 4.9 - Representative photographs, of immunofluorescence 
staining of human bone marrow cells. 
The expression of IL - IRI on MK cells was de termined 
by the staining with CD121a-FITG/CD41-PE antibodies 
(A, B and C) and the expression of IL- IRI I was detected 
by CD61-FITC/GDr21b-PE antibodies (D, E and F). All 
photographs >vere taken at 1000 x original magnification. 
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CHAPTER FIVE 
RESULTS AND DISCUSSION 
EFFECTS OF IL-ip ON THE EXPRESSIONS OF C-JUN, C-FOS, 
GATA-1 AND NF-E2 IN HUMAN MEGAKARYOCYTIC CELL 
LINES 
5.1 Dose dependency effect of IL-ip on the protein expression of 
transcription factors in Meg-01 cells 
Prior to treatments, Meg-01 cells were cultured in 1% FCS (serum starvation) 
overnight and there were 6.6% - 8.6% (mean range) and 15.8% - 19.4% cell death as 
determined by trypan blue exclusion assays before and after starvation, respectively. 
In two independent experiments, IL-1 (3 was added to the culture medium for 1 hr at a 
dose of 0, 5, 15, 20, 25，40 or 50 ng/ml to Meg-01 cells. The cell count and cell death 
were not affected by the IL-lp treatment. Representative autoradiograms of the total 
protein expressions determined by Western blot analysis of c-Jun, c-Fos, GATA-1 
and NF-E2 were shown in Figure 5.1. Our data demonstrated that IL-ip stimulated c-
Jim, c-Fos, GATA-1 and NF-E2 protein expressions in a dose-dependent manner. At 
25 ng/ml, IL-1 (3 enhanced the protein expressions of c-Jun, c-Fos, GATA-1 and NF-
E2 in Meg-01 cells to 3.7 fold (mean), 1.3 fold, 6.5 fold and 3.7 fold, respectively. 
Subsequent experiments were performed using 25 ng/ml of IL-1 p. The expression of 
actin was not altered by IL-1 (3. 
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5.2 Determination of RT-PCR condition by cycle titration 
To examine the mRNA expression in IL-lp treated MK cells, a cycle titration study 
(22-40 cycles) using equal amounts of DNA template was performed to optimize the 
PGR condition for c-Jun (Figure 5.2), c-Fos (Figure 5.3) and GATA-1 (Figure 5.4) 
genes. Twenty six cycles, 30 cycles and 25 cycles were selected for c-Jun, c-Fos and 
GATA-1 respectively for subsequent mRNA studies. Cycle titration of NF-E2 and 
PDH genes were previously established in our laboratory (Data not shown). All 
primer pairs selected did not give any signal from genomic DNA or reverse 
transcriptase reactions lacking the reverse transcriptase. There was no genomic DNA 
contamination in the PGR products in all RT-PCR experiments. 
5.3 Effects of IL-ip on c-Jun, c-Fos, GATA-1 and NF-E2 mRNA 
expression in Meg-01 and CHRF cells by Southern blot analysis 
The PGR products of c-Jun, c-Fos, GATA-1 and NF-E2 had the expected molecular 
size of 528 bp, 280 bp, 306 bp and 336 bp respectively, as determined by 
(t)174/HaeIII markers. In four and three independent experiments, Meg-01 and CHRF 
cells were exposed to IL-ip for 0, 15, 30, 60, 120 or 240 min. Representative 
autoradiograms of the Southern blot analysis of mRNA expression were shown in 
Figure 5.5. Expression intensities were corrected by the respective expressions of 
PDH. Results were expressed as the intensities of the transcription factors relative to 
those at 0 time point. The effects of IL-1 (3 on the mRNA expression of NF-E2 at 0, 
60, 120 and 240 min time-point in Meg-01 cells have been previously established in 
our laboratory. These results were independently presented (Yang et al, 2000). 
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Compared with the expression of PDH which did not change with time, there were 
rapid responses to IL-ip within 15 to 60 min of exposure, particularly for c-Jun, c-
Fos of which the mRNA levels peaked at 15 min and gradually subsided to the basal 
level after 240 min. The response of NF-E2 appeared comparatively slower and 
peaked about 120 min and 240 min after exposure in Meg-01 and CHRF cell 
respectively. The mRNA levels of c-Jun, c-Fos, GATA-1 and NF-E2 in Meg-01 cells 
were increased to 2.6 fold (mean, 15 min), 2 fold (15 min), 2 fold (60 min) and 5.2 
fold (240 min), respectively (Figure 5.5, left-hand panels). The mRNA levels of c-
Jun, c-Fos, GATA-1 and NF-E2 in CHRF cells were increased to 2.9 fold (15 min), 
3.9 fold (15 min), 2.4 fold (60 min) and 5.1 fold (120 min), respectively (Figure 5.5, 
right-hand panels). 
5.4 Effects of IL-ip on c-Jun, c-Fos, GATA-1 and NF-E2 protein 
expression in Meg-01 and CHRF cells by Western blot analysis 
The stimulatory effect of IL-1 (3 on these transcription factors was further confirmed 
by Western Blotting. Representative autoradiograms of the Western blot analysis of 
protein expression of c-Jun, c-Fos, GATA-1 and NF-E2 were shown in Figure 5.6. 
Results were expressed as the ratio of the intensity of the transcription factor to Actin. 
Results for the protein expression of NF-E2 in Meg-01 cells were previously 
established in our laboratory (data not shown) (Yang et al, 2000). In three and two 
independent experiments on Meg-01 and CHRF cells respectively, protein expression 
of c-Jun, c-Fos, GATA-1 and NF-E2 were induced by IL-1 (3. The expressions peaked 
at 30 min for c-Jun and c-Fos, 60 min for GATA-1 and 120 min for NF-E2 after 
exposure to IL-ip during which Actin levels were unaffected. The effects of IL-1 (3 
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on the protein expressions of c-Jun and c-Fos decreased gradually to the basal levels 
after 240 min in both cell lines. The expressions of GATA-1 and NF-E2 decreased 
gradually but did not reach the basal levels. In Meg-01 cells, the protein expressions 
of c-Jun, c-Fos and GATA-1 were increased to 2.7 fold (mean, 30 min), 2.6 fold (30 
min) and 5.9 fold (60 min), respectively (Figure 5.6，left-hand panels). In CHRF cells, 
the protein expressions of c-Jun, c-Fos, GATA-1 and NF-E2 were increased to 3 fold 
(30 min), 1.7 fold (30 min), 11.5 fold (60 min) and 12.5 fold (120 min), respectively 
(Figure 5.6, right-hand panels). 
5.5 Effects of IL-ip on c-Jun, c-Fos, GATA-1 and NF-E2 nuclear 
accumulation in Meg-01 and CHRF cells by Western blot analysis 
The effects of IL-1 (3 on c-Jun, c-Fos, GATA-1 and NF-E2 protein expression were 
further confirmed using nuclear protein extracts as the active forms of the 
transcription factors were expected to be translocated into the cell nucleus after 
stimulation. Representative autoradiograms of the Western blot analysis of the 
nuclear accumulations of c-Jun, c-Fos, GATA-1 and NF-E2 were shown in Figure 5.7. 
Our results demonstrated that IL-1 (3 significantly enhanced the nuclear 
accumulations of c-Jun, c-Fos, GATA-1 and NF-E2 to 9.3 fold (30 min), 3.3 fold (30 
min), 8.5 fold (60 min) and 6.5 fold (240 min), respectively in Meg-01 cells (Figure 
5.7, left-hand panels). In CHRF cells, IL-1 (3 also significantly enhanced the nuclear 
accumulations of c-Jun, c-Fos, GATA-1 and NF-E2 to 5.1 fold (30 min), 4.3 fold (30 
min), 2.3 fold (60 min) and 15.1 fold (120 min), respectively (Figure 5.7, right-hand 
panels). The protein expressions of c-Jun, c-Fos and GATA-1 decreased gradually to 
the basal levels after 240 min in both cell lines. For NF-E2, the protein expression 
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decreased gradually but did not reach the basal levels. 
5.6 Discussion 
Signal transduction initiated by the interactions of growth factors with specific 
receptors was an important mechanism for regulating cell survival, proliferation and 
differentiation. In chapter 4，we demonstrated the proliferative effect of IL-1 p on the 
MK lineage and the expressions of IL-1 p and receptors on primary human MK cells 
and cell lines. These led us to investigate the signal transduction mechanism of IL-1 (3 
in this lineage. Meg-01 and CHRF cells were employed as the models for studying 
the effects of IL-1 p on the expression of transcription factors as they exhibited strong 
expression of IL-1 receptors. The Dami cell line has been studied extensively as a 
model for the MK lineage and it expressed high levels of IL-1 receptor. However, a 
recent study has suggested that the Dami cell line might be contaminated with HEL 
erythroleukemia (Roderick et al, 1997), and therefore it was not further studied in the 
chapter. 
Nearly every signal transduction system was known to be responsive to IL-1 
activation in various cell types (Bankers-Fulbright et al, 1996). In the MK lineage, 
the signal transduction of IL-1 has not been reported. Our study demonstrated that 
the transcription factors c-Jun, c-Fos, GATA-1 and NF-E2 were detectable at low 
levels in Meg-01 and CHRF and they were up-regulated upon stimulation by IL-ip 
in a time- and dose-dependent manner. The activation of these transcription factors 
was specific and consistent at the mRNA and protein levels in the total or nuclear cell 
lysates. The response to IL-1 (3 was fast, being within 15-30 min of induction and the 
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levels subsided at 2 hr except for NF-E2 of which the response was consistently 
slower. 
c-Jun and c-Fos have been implicated in a wide variety of cell types, such as 
monocytes, polymorphs, and immature erythroblasts, as well as CD34+ cells and 
activated lymphocytes (Bertani et al, 1989; Gonda and Metcalf, 1984; Sariban et al, 
1988; Caubet et al, 1989; Kastan et al, 1989), as immediate early genes responding 
to stimulation by serum, growth factors, or phorbol ester. These transcripts were also 
detected in cultured or fresh marrow megakaryocytes (Mouthon et al, 1992). In many 
cell types including blood cell lineage, the major transcription factors associated with 
IL-1 stimulation were N F - K B , NF-IL-6 and AP-1 (Bankers-Fulbright et al, 1996). 
AP-1, a substrate of MAP kinases, was the heterodimer of c-Jun and c-Fos that were 
strongly implicated in the regulation of cell proliferation and differentiation. Our 
results demonstrated that IL-lp exerted growth stimulating effects on the MK lineage 
(Section 4.1) and the mechanism might possibly involve c-Jun and c-Fos. 
The GATA-1 and NF-E2 genes were established transcription factors of the MK 
lineage. The GATA-1 gene served multiple functions in MK development, 
influencing cellular growth, maturation (Vyas et al, 1999) and gene activation 
(Shivdasani, 1997). GATA-1-deficient mice expressed markedly lower levels ofMK-
associated genes including platelet factor-4, c-mpl, and p45 NF-E2 (Vyas et al, 1999), 
indicating that these proteins might be target genes of GATA-1 (Deveanx et al, 1996; 
Hashimoto and Ware, 1995; Minami et al, 1998). Expression of p45 NF-E2 was 
restricted to erythroid precursors, MK cells, mast cells, and multipotential 
progenitors. It was required for granules formation within megakaryocytes. NF-E2 
was shown to be stimulated by TPO, which induced differentiation markers, 
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GPIIb/IIIa and Pm-1 (Romeo et al, 1990). NF-E2 was known to affect the expression 
of globin genes in developing erythroid cells through the upstream AP-1-like 
recognition sites (Andrews et al, 1993). NF-E2 has been reported to induce MK cell 
terminal differentiation and platelet development (Shivdasani and Orkin, 1995). Our 
study demonstrated the up-regulation of GATA-1 and NF-E2 by IL-ip and suggested 
that IL-1 (3 might play an important role in megakaryocytopoiesis. 
In summary, our results demonstrated for the first time the specific stimulation of IL-
Ip on the expressions of c-Jun, c-Fos, GATA-1 and NF-E2. These transcription 
factors might be elements of the signal transduction pathway of IL-lp in the 
regulation of megakaryocytopoiesis. 
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Figure 5.1 - Effects of IL-lp on c-Jun, c-Fos, GATA-1 and NF-E2 
protein expression in Meg-01 cells. 
Meg-01 cells were incubated with the indicated concentration of IL-
1P for 1 hr and then harvested for total protein. Protein expressions 
were investigated by Western blot analysis, (n = 2; mean 士 S.E.M.) 
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Figure 5.2 - Cycle titration of c-Jun. 
(A) Southern blot analysis of the expression of c-Jun using equal 
amounts of DNA template with different numbers of PCR cycles 
(22-40). (B) Cycle titration curve: optical density with respect to 
different numbers of PCR cycle scanned from densitometer. 
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Figure 5.3 - Cycle titration of c-Fos. 
(A) Southern blot analysis of the expression of c-Fos using equal 
amounts of DNA template with different numbers of PCR cycles 
(22-40). (B) Cycle titration curve: optical density with respect to 
different numbers of PCR cycle scanned from densitometer. 
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Figure 5.4 - Cycle titration of GATA-1. 
(A) Southern blot analysis of the expression of GATA-1 using equal 
amounts of DNA template with different numbers of PCR cycles (15-
40). (B) Cycle titration curve: optical density with respect to 
different numbers of PCR cycle scanned from densitometer. 
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Figure 5.5 - Effects of IL-1 P on the mRNA expressions of c-Jun, c-Fos, 
GATA-1 and NF-E2. 
The mRNA expression was detected by RT-PCR and confirmed by 
Southern blot analysis of Meg-01 (left-hand panels) and CHRF 
(right-hand panels) cells. PDH was used as a control of RNA quality. IL-ip 
at 25 ng/ml stimulated the expression of c-Jun, c-Fos, GATA-1 
and NF-E2. Results were presented as the ratio of the expression 
intensities of the transcription factors: PDH and relative to the 
0 time point in mean 土 S.E.M. (n == 4 for Meg-01 and n = 3 for CHRF) 
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Figure 5.6 - Effects of IL-1 (3 on the total protein expression of c-Jun, c-Fos, 
GATA-1 and NF-E2. 
Meg-01 (left-hand panels) and CHRF (right-hand panels) cells were treated 
with IL-lp at 25 ng/ml for 0 - 240 min and the total protein expression 
was detected by Western blot analysis. Actin expression was used as a 
loading control, (n = 3 for Meg-01 and n 二 2 for CHRF; mean 土 S.E.M.) 
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Figure 5 . 7 - Effects of IL-1 p on the nuclear accumulations of c-Jun, c-Fos, 
GATA-1 and NF-E2. 
Meg-01 (left-hand panels) and CHRF (right-hand panels) cells were treated 
with IL-ip at 25 ng/ml for 0 — 240 min and the nuclear accumulation was 
detected by Weste rn blot ana lys is , (n 二 1; mean 士 S .E.M.) 
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CHAPTER SIX 
RESULTS AND DISCUSSION 
MECHANISM OF ACTIVATION OF THE SIGNAL 
TRANSDUCTION PATHWAY BY IL-ip ON HUMAN 
MEGAKARYOCYTIC CELL LINE CHRF-288-11 
6.1 Effects of recombinant human IL-1 receptor antagonist (IL-lRA) on 
the nuclear accumulations of c-Jun, c-Fos, GATA-1 and NF-E2 
induced by IL-ip 
6.1.1 mRNA expressions of c-Jun, c-Fos, GATA-1 and NF-E2 
CHRF cells were exposed to increasing concentrations of IL-IRA at 125，250 or 500 
ng/ml overnight, followed by stimulation with IL-ip (25 ng/ml) for 1 hr. Our results 
showed that the total nucleated cell count and cell death were not affected by the IL-
ip and IL-IRA treatments in this period. The Southern blot analysis demonstrated 
that IL-IRA reduced the stimulatory effect of IL-ip on c-Jun, c-Fos, GATA-1 and 
NF-E2 mRNA expressions in a dose-dependent manner (Figure 6.1). IL-IRA alone 
did not induce any mRNA expression. 
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IL-lp enhanced the mRNA expressions of c-Jun, c-Fos, GATA-1 and NF-E2 by 1.83 
fold (mean), 6.11 fold, 4 fold and 3.6 fold, respectively. At 125 ng/ml, IL-IRA 
inhibited the mRNA expressions of c-Jun, c-Fos, GATA-1 and NF-E2 by 9.8%, 
11.30/0, 14.8% and 31.2%, respectively. At 500 ng/ml of IL-IRA, IL-lp-induced 
mRNA expressions of c-Jun, c-Fos, GATA-1 and NF-E2 were significantly inhibited 
by 31.1%, 88.50/0, 54.6% and 61.6%, respectively. Complete inhibition of IL-1 p 
stimulated mRNA expression was not observed. The expression of PDH was not 
altered by IL-ip and IL-IRA. 
6.1.2 Nuclear accumulations of c-Jun, c-Fos, GATA-1 and NF-E2 
The dose-dependent inhibitory effect of IL-IRA on the IL-ip-induced nuclear 
accumulation of transcription factors were confirmed by Western blot analysis, and 
illustrated in Figure 6.2. IL-1 (3 (25 ng/ml, incubated for 1 hr) enhanced the nuclear 
accumulations of c-Jun, c-Fos, GATA-1 and NF-E2 by 2.3 fold, 3.1 fold, 2.8 fold and 
6.4 fold, respectively. IL-IRA (125 ng/ml) inhibited nuclear accumulations of c-Jun, 
c-Fos, GATA-1 and NF-E2 by 14.6%, 8%, 26.2% and 28.6%, respectively. At 500 
ng/ml, the inhibitory effects were further amplified and IL-IRA inhibited the nuclear 
accumulations of c-Jun, c-Fos, GATA-1 and NF-E2 by 49.3%, 51.5%, 54.7% and 
77.30/0, respectively. IL-IRA alone did not induce any nuclear accumulation. 
Complete inhibition of IL-1 p stimulated nuclear accumulation was not observed. 
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6.2 Effects of IL-lp on TPO mRNA expression in Meg-01 and CHRF cells 
by Southern blot analysis 
6.2.1 Determination of RT-PCR condition of TPO by cycle titration 
A cycle titration study (18-40 cycles) using equal amounts of DNA template was 
performed to optimize the PCR condition for TPO (Figure 6.3) mRNA expression. 
Twenty-seven cycles were selected for TPO mRNA studies in subsequent 
experiments. All primer pairs selected did not give any signal from genomic DNA or 
reverse transcriptase reactions lacking the reverse transcriptase. There was no 
genomic DNA contamination in the PCR products in all RT-PCR experiments. 
6.2.2 Effect of IL-1 p on TPO mRNA expression in Meg-01 and CHRF cells 
The PCR product had the expected molecular size of 377 bp as determined by 
(|)174/HaeIII markers. In four and three independent experiments respectively, Meg-
01 and CHRF cells were exposed to IL-ip for 0, 15, 30, 60, 120 or 240 min. 
Representative autoradiograms of the Southern blot analysis of mRNA expression of 
TPO were shown in Figure 6.4. Results were expressed as the ratio of the intensity of 
TPO to PDH. There were gradual responses to IL-ip within 15 - 120 min of 
exposure. The mRNA expression of TPO peaked at 120 min of exposure to IL-1 (3 
and gradually subsided in Meg-01 cells (Figure. 6.4, left-hand panel). The mRNA 
expression of TPO was not detectable in untreated Meg-01 cell culture. Therefore the 
results were expressed in relative exposure of TPO to PDH, instead of the fold 
increase in comparison to the expressions at 0 time point. Moreover, the mRNA level 
of TPO in CHRF cells peaked at 120 min with 7.8 fold increase (mean), and 
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gradually subsided after 240 min (Figure 6.4, right-hand panel). PDH expression was 
not affected by IL-1 p. 
6.3 Effects of anti-human TPO neutralizing antibody (TPO Ab) on the 
nuclear accumulations of c-Jun, c-Fos, GATA-1 and NF-E2 induced by 
IL-lp 
To investigate the possibility that the IL-ip enhanced mRNA and nuclear 
accumulations of c-Jun, c-Fos, GATA-1 and NF-E2 were mediated by TPO secretion 
in response to IL-1 (3 treatment, CHRF cells were cultured with IL-ip (25 ng/ml) and 
the effects of increasing concentrations of TPO Ab (0, 5, 10 or 15 |Lig/ml, incubated 
for 2 hr) were determined by RT-PCR, Southern blot and Western blot analysis. Our 
data demonstrated that total cell count and cell death were not affected by the IL-1 (3, 
TPO Ab, TPO and control IgG Ab treatments in the culture duration. 
6.3.1 Effects of anti-human TPO neutralizing antibody (TPO Ab) on the nuclear 
accumulations of GATA-1 and NF-E2 induced by IL-ip 
6.3.1.1 mRNA expressions of GATA-1 and NF-E2 
IL-ip (incubated for 1 hr) enhanced the mRNA expressions of GATA-1 and NF-E2 
by 2 fold (mean) and 2.5 fold, respectively. The addition of TPO Ab to the culture 
had only slight effects on the mRNA expressions of GATA-1 and NF-E2 (Figure 6.5). 
At 15 j ig /ml of TPO Ab, the mRNA expressions of GATA-1 and NF-E2 were 
decreased by 20.5% and 19%. The addition of control IgG did not affect the 
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expression of those transcription factors. PDH expression was not affected by IL-ip, 
TPO Ab and control IgG. 
6.3.1.2 Nuclear accumulations of GATA-1 and NF-E2 
The effects of TPO Ab on the IL-ip-induced nuclear accumulations of GATA-1 and 
NF-E2 were demonstrated in Figure 6.6. IL-ip (25 ng/ml, incubated for 1 hr) 
enhanced the nuclear accumulations of GATA-1 and NF-E2 by 4.8 fold and 4.4 fold, 
respectively. TPO Ab at 15 |Lig/ml decreased the nuclear accumulations of GATA-1 
and NF-E2 by 31.1% and 14.7%, respectively. The addition of control IgG did not 
affect the expression of those transcription factors. 
6.3.2 Effects of anti-human TPO neutralizing antibody (TPO Ab) on the nuclear 
accumulations of c-Jun and c-Fos induced by IL-1 (3 
6.3.2.1 mRNA expressions of c-Jun and c-Fos 
In two independent experiments, IL-ip treatment for 30 min instead of 60 min was 
performed because the induction of c-Jun and c-Fos by IL-ip peaked at 30 min. IL-
ip (25 ng/ml, incubated for 30 min) enhanced the mRNA expressions of c-Jun and c-
Fos by 3.9 fold (mean) and 3.4 fold, respectively (Figure 6.7). At 15 jug/ml of TPO 
Ab, the mRNA expressions of c-Jun and c-Fos were decreased by 17.9% and 5.9%. 
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TPO (15 ng/ml, incubated for 30 min) enhanced the mRNA expressions of c-Jun and 
c-Fos by 3.1 fold (mean) and 2.9 fold, respectively. In the presence of TPO Ab, the 
mRNA expressions of c-Jun and c-Fos induced by TPO were reduced by 83.9% and 
62.1%, respectively. The addition of TPO Ab only did not affect the expression of 
those transcription factors. PDH expression was not affected by IL-ip, TPO Ab and 
TPO. 
6.3,2.2 Nuclear accumulations of c-Jun and c-Fos 
The effects of TPO Ab on the IL-ip-induced nuclear accumulations of c-Jun and c-
Fos were demonstrated in Figure 6.8. IL-ip (25 ng/ml, incubated for 30 min) 
enhanced the nuclear accumulations of c-Jun and c-Fos by 6.1 fold (mean) and 5 fold, 
respectively. At 15 jig/ml of TPO Ab, the nuclear accumulations of c-Jun and c-Fos 
were decreased by 1.6% and 2%. 
TPO (15 ng/ml, incubated for 30 min) enhanced the nuclear accumulations of c-Jun 
and c-Fos by 4.7 fold (mean) and 4.2 fold, respectively. In the presence of TPO Ab, 
the nuclear accumulations of c-Jun and c-Fos induced by TPO were reduced by 66% 
and 64%, respectively. The addition of TPO Ab only did not affect the expression of 
those transcription factors. 
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6.4 Effects of Actinomycin D (ActD) and Cycloheximide (CHX) on the 
nuclear accumulations of c-Jun, c-Fos, GATA-1 and NF-E2 induced by 
IL-ip 
To determine whether the increase in mRNA and nuclear accumulations of c-Jun, c-
Fos, GATA-1 and NF-E2 following IL-ip treatment were mediated by protein 
synthesis of those genes, CHRF cells were cultured with IL-ip (25 ng/ml, incubated 
for 1 hr) and effects of increasing concentrations of ActD (0, 5, 10, 50, 100 or 500 
ng/ml, incubated for 2 hr) and CHX (0, 0.1, 0.5, 1 or 2 |ag/ml, incubated for 2 hr) 
were studied by RT-PCR, Southern blot and Western blot analysis. Total nucleated 
cell count and cell death were not significantly affected by the IL-ip, ActD and CHX 
treatments within the study period. 
CHRF cells pre-treated with increasing levels of ActD and CHX showed a dose-
dependent decrease in levels of mRNA and nuclear accumulations of c-Jun, c-Fos, 
GATA-1 and NF-E2 in response to IL-1 (3. Neither ActD nor CHX alone had an effect 
on the mRNA and nuclear accumulations. No effects of 100% ethanol were 
detectable (data not shown in experiments with ActD). 
6.4.1 Effects of Actinomycin D (ActD) on the nuclear accumulations of c-Jun, c-
Fos, GATA-1 and NF-E2 induced by IL-lp 
6.4.1.1 mRNA expressions of c-Jun, c-Fos, GATA-1 and NF-E2 
In Figure 6.9, IL-1 (3 (25 ng/ml, incubated for 1 hr) enhanced the mRNA expressions 
of c-Jun, c-Fos, GATA-1 and NF-E2 by 3.3 fold (mean), 4 fold, 3.8 fold and 6.8 fold, 
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respectively. ActD inhibited mRNA responses of c-Jun, c-Fos, GATA-1 and NF-E2 
in a dose-dependent manner. At 500 ng/ml of ActD, the IL-ip-induced mRNA 
expressions of c-Jun, c-Fos, GATA-1 and NF-E2 were significantly inhibited by 
33.1%, 55.8%, 55.6% and 70.1%, respectively. PDH expression was not affected by 
IL-ip and ActD. 
6.4.1.2 Nuclear accumulations of c-Jun, c-Fos, GATA-1 and NF-E2 
The dose-dependent inhibitory effect of ActD on the IL-ip-induced nuclear 
accumulation of transcription factors were demonstrated in Figure 6.10. IL-ip (25 
ng/ml, incubated for 1 hr) enhanced the nuclear accumulations of c-Jun, c-Fos, 
GATA-1 and NF-E2 by 3.2 fold, 2.9 fold, 4.5 fold and 2.1 fold, respectively. At 500 
ng/ml of ActD, it significantly inhibited the nuclear accumulations of c-Jun, c-Fos, 
GATA-1 and NF-E2 by 52.7%, 41%, 42.4% and 70%, respectively. 
6.4.2 Effects of Cycloheximide (CHX) on the nuclear accumulations of c-Jun, c-
Fos, GATA-1 and NF-E2 induced by IL-ip 
6.4.2.1 mRNA expressions of c-Jun, c-Fos, GATA-1 and NF-E2 
IL-ip (25 ng/ml, incubated for 1 hr) enhanced the mRNA expressions of c-Jun, c-Fos, 
GATA-1 and NF-E2 by 4.2 fold (mean), 4 fold, 3.9 fold and 2.5 fold, respectively 
(Figure 6.11). CHX inhibited mRNA expressions of c-Jun, c-Fos, GATA-1 and NF-
E2 in a dose-dependent manner. PDH expression was not affected by IL-ip and CHX. 
At 2 [ig/m\ of CHX, it significantly inhibited the IL-ip-induced mRNA expressions 
of c-Jun, c-Fos, GATA-1 and NF-E2 by 40.4%, 45.3%, 50.1% and 24.5%, 
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respectively. 
6.4.2.2 Nuclear accumulations of c-Jun, c-Fos, GATA-1 and NF-E2 
The dose-dependent inhibitory effect of CHX on the IL-ip-induced nuclear 
accumulation of transcription factors were demonstrated in Figure 6.12. The nuclear 
accumulations of c-Jun, c-Fos, GATA-1 and NF-E2 were enhanced by 2.5 fold, 2.4 
fold, 2.2 fold and 6.3 fold, respectively. At 2 \ig/m\ of CHX, it significantly inhibited 
the nuclear accumulations of c-Jun, c-Fos, GATA-1 and NF-E2 by 60.1%, 59.1%, 
40.8% and 72.7%, respectively. 
6.5 Discussion 
The expression of IL-1 receptors in the MK cell lines and the rapid and specific 
response of c-Jun, c-Fos, GATA-1 and NF-E2 to IL-ip indicated that IL-ip exerted 
direct effects on these cells. This was further confirmed by the addition of IL-IRA, 
an IL-1 receptor antagonist, which was reported to bind to IL-IRI and IL-IRII of 
human cells (Granowitz et al, 1991). It competed with IL-1 and blocked binding of 
IL-1 to its receptor equally as well as the naturally-occurring, glycosylated form. IL-
IRA administration in vivo abolished IL-1 mediated inflammatory responses 
(Gershenwald et al, 1990), as well as IL-1-induced production of IL-1, IL-6 and 
TNF-a in human monocytes (Granowitz et al, 1992). Administration of IL-IRA 
reduced both the immunosuppression and the mortality of murine graft-versus-host-
disease after bone marrow transplantation without impairing the engraftment of 
hematopoietic stem cells (McCarthy et al, 1991). Although IL-IRA had the same 
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affinity for IL-1 receptor-bearing cells as IL-1 (3, at least a 10-fold molar excess has 
been required to block the biological activity of IL-lp because only very few 
receptors were needed for IL-ip activation (Rasmussen et al, 1997). Accordingly, 
our data demonstrated that a 20-fold molar excess of IL-1 RA significantly inhibited 
the enhancing effects of IL-113 on the nuclear accumulations of c-Jun, c-Fos, GATA-1 
and NF-E2, indicating that the mechanism of IL-1 (3 on these transcription factors was 
mediated, in majority, by IL-1 receptors. The inhibitory effect of IL-1 RA, though not 
complete, was up to 77%. Although it has been reported that IL-IRA had mild 
agonist activity in human endometrial epithelial cell line in higher concentrations (10 
ng/ml) (Kniss et al, 1997), this was not detected in our system. 
ActD formed a stable complex with double-stranded DNA and inhibited RNA 
synthesis. Morphologically, ActD-treated cells underwent apoptosis and displayed 
cell shrinkage, a more rounded cell shape, increased cell detachment and nuclear 
condensation (Kleeff et al, 2000). CHX inhibited protein synthesis in eukaryotic cells 
by blocking translation of messenger RNA on the ribosome. The effects of IL-113 on 
the mRNA and nuclear accumulations of c-Jun, c-Fos, GATA-1 and NF-E2 were 
strongly inhibited by ActD and CHX, which demonstrated that the stimulation of 
these transcription factors likely involved the synthesis of RNA and proteins, rather 
than the activation of existing proteins. The partial reduction of IL-ip-induced 
mRNA and nuclear accumulation of those transcription factors might reflect the fact 
that the 500 ng/ml ActD and 2 |ig/ml CHX concentrations were not sufficient to 
completely inhibit mRNA and nuclear accumulations. Higher concentrations of ActD 
and CHX were not used in our study because they were highly toxic to the cells. 
ActD at 1000 ng/ml on pancreatic cancer cells (Kleeff et al, 2000) and CHX at 10 
^ig/ml on B lymphocytes (Christophe et al, 1999) have been suggested for complete 
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inhibition of RNA and protein synthesis. Therefore, we chose the dose range from 5 
to 500 ng/ml ActD and 0.1 to 2 fig/ml CHX in these experiments. 
TPO was an essential regulator of megakaryocytopoiesis and thrombopoiesis. In our 
study, we demonstrated that TPO mRNA was expressed in CHRF but not in Meg-01 
at the basal level. Upon stimulation by IL-lp, TPO expression was increased to over 
7.8 fold at 120 min. To our knowledge, this was the first report on the induction of 
TPO expressions by IL-lp in MK cells. 
Signal transduction pathways of TPO in the MK lineage were essentially established 
by the binding of TPO to its cell surface receptor c-Mpl. Mpl receptor expression has 
been detected in human hematopoietic cells throughout the MK lineage, in primitive 
CD34+CD38- cells (Debili et al, 1995). TPO has been reported to stimulate the 
transcription factors GATA-1 and NF-E2, which induced MK differentiation markers, 
GPIIb/IIIa and Pm-1 (Nagata et al, 1997), and thus helped to promote MK 
development and maturation. TPO could also affect platelet functions through the 
p38 pathway (Ezumi et al, 1999). In our study, we demonstrated that TPO at 15 
ng/ml stimulated the expressions of c-Jun and c-Fos. Thus, it has been a concern 
whether the response of c-Jun, c-Fos, GATA-1 and NF-E2 to IL-ip was a secondary 
effect, mediated by the induction of TPO. To investigate such a possibility, we pre-
treated the CHRF cells with an excess of TPO neutralizing antibody. Our data 
demonstrated that the TPO antibody had no significant effect on the IL-1 p-induced 
mRNA and nuclear accumulations of c-Jun, c-Fos, GATA-1 and NF-E2, indicating 
that those expressions were independent of the action of TPO. According to the 
manufacturer's instruction, the neutralization dosejo (ND50) for this antibody was 5 -
10 jig/ml in the presence of 10 ng/ml human TPO. As it was highly unlikely that the 
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concentration of TPO present in the medium (with 1% FCS) together with that 
synthesized by the cells in 30 min reached 10 ng/ml, we chose the dose range of 
neutralizing antibody at 5 to 15 |Lig/ml. Although IL-lp might induce the synthesis of 
other cytokines such as GM-CSF or IL-6, the rapid and specific response (as early as 
15 min) of the transcription factors to IL-ip, strongly suggested that IL-lp exerted 
direct stimulating effects on the expressing of these factors. 
In summary, our study investigated the possible direct effect of IL-1 (3 on the up-
regulation of c-Jun, c-Fos, GATA-1 and NF-E2 in CHRF cells. The mechanism was 
mediated by the IL-IRI and involved mRNA and nuclear protein synthesis. Although 
IL-1 (3 also induced the expression of TPO, it appeared that the induction of these 
transcription factors was not secondary to the secretion of TPO. 
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Figure 6.1 - Effects of IL-IRA on IL-lp-induced mRNA expressions of c-
Jun, c-Fos, GATA-1 and NF-E2. 
CHRF cells were starved overnight with increasing concentrations (125, 
250 or 500 ng/ml) of IL-IRA before cells were incubated with or without 
IL-ip (25 ng/ml) for 1 hr. Control cultures received medium alone during 
the time period. The mRNA expressions were investigated by RT-PCR 
and Southern blot analysis. Results were adjusted according to the 
respective intensities of PDH expression and presented as the ratio to the 
expression intensities of untreated samples, (n = 2; mean 士 S.E.M) 119
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Figure 6.2 — Effects of IL-IRA on IL-ip-induced nuclear 
accumulations of c-Jun, c-Fos, GATA-1 and NF-E2. 
CHRF cells were starved overnight with increasing concentrations 
(125，250 or 500 ng/ml) of IL-IRA before cells were incubated 
with or without IL-ip (25 ng/ml) for 1 hr. Control cultures 
received medium alone during the time period. Nuclear 
accumulations were investigated by Western blot analysis. Results 
were expressed as the nuclear accumulations relative to those 
in untreated culture and presented as mean 士 S.E.M. (n = 2) 
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Figure 6.3 - Cycle titration of TPO. 
(A) Southern blot analysis of the expression of TPO was performed 
using equal amounts of DNA template with different numbers of PCR 
cycles (18-40). (B) Cycle titration curve: optical density with respect 
to different numbers of PCR cycle scanned from densitometer. 
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Figure 6.4 - Effects of IL-1 (3 on the mRNA expressions of TPO. 
The mRNA expression was detected by RT-PCR and confirmed 
by Southern blot analysis of Meg-01 (left-hand panels) and CHRF 
(right-hand panels) cells. PDH was used as a control of RNA quality. IL-ip 
at 25 ng/ml stimulated the mRNA expression of TPO. Results 
were presented as the ratio of the expression intensities of the TPOiPDH 
in mean 土 S.E.M. for Meg-01 (n = 4). Those for CHRF (n = 3) were 
adjusted according to the respective intensities of PDH expression and 
presented as the ratio to the expression intensities of untreated samples. 
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Figure 6.5 一 Effects of TPO neutralizing antibody on IL-ip-induced 
mRNA expressions of GATA-1 and NF-E2. 
CHRF cells were cultured for 2 hr with increasing concentrations (5, 10 
or 15 |ag/ml) of TPO Ab before these cells were incubated with or 
without IL-ip (25 ng/ml) for 1 hr. Control cultures received medium 
alone during the time period. mRNA expressions were investigated by 
RT-PCR and Southern blot analysis. Results were adjusted according to 
the respective intensities of PDH expression and presented as the ratio to 
the expression intensities of untreated samples, (n = 2; mean 土 S.E.M.) 
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Figure 6.6 - Effects of TPO neutralizing antibody on IL-ip-induced 
nuclear accumulations of GATA-1 and NF-E2. 
CHRF cells were cultured for 2 hr with increasing concentrations 
(5, 10 or 15 |ig/ml) of TPO Ab before these cells were incubated 
with or without IL- ip (25 ng/ml) for 1 hr. Control cultures 
received medium alone during the time period. Nuclear 
accumulations were investigated by Western blot analysis. Results 
were expressed as the nuclear accumulations relative to those in 
untreated culture and presented as mean 士 S.E.M. (n = 2) 124 
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Figure 6.7 - Effects of TPO neutralizing antibody on IL-ip-induced mRNA 
expressions of c-Jun and c-Fos. 
CHRF cells were cultured for 2 hr with increasing concentrations (5, 10 or 
15 |j.g/ml) of TPO Ab before these cells were incubated with or without IL-
IP (25 ng/ml) for 30 min. TPO (15 ng/ml) with or without TPO Ab (15 
|j,g/ml) were acted as control. Control cultures received medium alone 
during the time period. mRNA expressions were investigated by RT-PCR 
and Southern blot analysis. Results were adjusted according to the 
respective intensities of PDH expression and presented as the ratio to the 
expression intensities of untreated samples, (n = 2; mean 土 S.E.M.) 125 
RESULTS AND DISCUSSION: CHAPTER SIX 
^ CD. CO. O 
CCL r-H r-H ^ 
3 d d ^ 
T ± ± 5 3 < < r ^ 力 二 O o o n o S P 客 ¥ & 2 & ^ Cd Ph H H H ft — 
I ^ I I I J I ^  
H-) T-H ITI R-H — — 二 H 
jUgm^ ^^^NIP i^ iij^ fc ‘ 
c-Fos ：等 mtiK^ mm ^mmm ^ m m - - - 等' 
— — •IL-l(-) 
9 厂 8 - SIL-1(+) 
守7 - T 
1 lIL-l(+),TPOAb: 
t I T T T T 5ug/ml(+) 
1 5 - ^ p l i i i i i M ^ l On^ lBITOAb: 
霞 4 - 丨丨丨；丨 10ug/ml(+) 
8 3 — ^ p i l i i i ^ p i i a w x i T O A b： I , ^ ^ 圓 T ^ P ^ i I T T 職+) 
BSSSM l\s\\N::::: l-sytif^ ^H tSSSSiL—i^ �\�v ::::: 
0 ^ M ^ J ^ g j M t^TPor+iTPOAb： 
15ug/ml(+) c-Jun c-Fos •lL-l(-),TPOAb(+)    
Figure 6.8 — Effects of TPO neutralizing antibody on IL-1 (3-induced 
nuclear accumulations of c-Jun and c-Fos. 
CHRF cells were cultured for 2 hr with increasing concentrations 
(5，10 or 15 |ag/ml) of TPO Ab before these cells were incubated with or 
without IL- lp (25 ng/ml) for 30 min. TPO (15 ng/ml) with or 
without TPO Ab (15 jig/ml) were acted as control. Control 
cultures received medium alone during the time period. Nuclear 
accumulat ions were invest igated by Western blot analysis . 
Results were expressed as the nuclear accumulations relative to those 
in untreated culture and presented as mean 土 S.E.M. (n = 2) 
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Figure 6.9 一 Effects of ActD on IL-lp-induced mRNA expressions of c-Jun, 
c-Fos, GATA-1 and NF-E2. 
CHRF cells were cultured for 2 hr with increasing concentrations (5，10, 50, 
100 or 500 ng/ml) of ActD before these cells were incubated with or without 
IL-ip (25 ng/ml) for 1 hr. Control cultures received medium or 100% 
ethanol alone during the time period. mRNA expressions were investigated 
by RT-PCR and Southern blot analysis. Results were adjusted according to 
the respective intensities of PDH expression and presented as the ratio to the 
expression intensities of untreated samples, (n 二 2; mean 土 S.E.M.) 
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Figure 6.10-Effects of ActD on IL-ip-induced nuclear accumulations of c-Jun, 
c-Fos, GATA-1 andNF-E2 . 
CHRF cells were cultured for 2 hr with increasing concentrations (5, 10，50， 100 or 500 ng/ml) of ActD before these cells were incubated with or without 
IL-ip (25 ng/ml) for 1 hr. Control cultures received medium or 100% ethanol 
alone during the time period. Nuclear accumulations were investigated by 
Western blot analysis. Results were expressed as the nuclear accumulations 
relative to those in untreated culture and presented as mean 士 S.E.M. (n = 2) 
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Figure 6.11 - Effects of CHX on IL-ip-induced mRNA expressions of c-
Jun, c-Fos, GATA-1 and NF-E2. 
CHRF cells were cultured for 2 hr with increasing concentrations (0.1, 0.5, 
1 or 2 |ig/ml) of CHX before these cells were incubated with or without 
IL-lp (25 ng/ml) for 1 hr. Control cultures received medium or 100% 
ethanol alone during the time period. mRNA expressions were investigated 
by RT-PCR and Southern blot analysis. Results were adjusted according to 
the respective intensities of PDH expression and presented as the ratio to 
the expression intensities of untreated samples, (n 二 2; mean 土 S.E.M.) 129 
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Figure 6 .12- Effects of CHX on IL-ip-induced nuclear accumulations 
of c-Jun, c-Fos, GATA-1 andNF-E2. 
CHRF cells were cultured for 2 hr with increasing concentrations 
(0.1，0.5, 1 or 2 |ig/ml) of CHX before these cells were incubated 
with or without IL-ip (25 ng/ml) for 1 hr. Control cultures received 
medium or 100% ethanol alone during the time period. Nuclear 
accumulations were investigated by Western blot analysis. Results 
were expressed as the nuclear accumulations relative to those 
in untreated culture and presented as mean 士 S.E.M. (n = 2) 
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CHAPTER SEVEN 
GENERAL DISCUSSION AND CONCLUSION 
The effects of IL-1 (3, the pro-inflammatory cytokine, on the in vitro and in vivo 
induction of megakaryocytopoiesis have been largely considered as indirect and 
mediated by other cytokines or accessory cells. Our hypothesis was that IL-ip 
exerted direct stimulating effects on MK cells and the mechanism involved its 
receptors IL-IRI /IL-IRII and the transcription factors c-Jun, c-Fos, GATA-1 and 
NF-E2. Our study models were megakaryoblastic cell lines Meg-01 and CHRP and 
primary murine and human MK cells. 
Our data demonstrated that IL-ip enhanced the formation of CFU-MK from murine 
bone marrow and enriched CD34+ cells from human cord blood, in the presence or 
absence of TPO. In addition, we identified the mRNA and protein expressions of IL-
lp, IL-IRI and IL-IRII in MK cell lines and primary cells. Our results further 
demonstrated that IL-lp stimulated the mRNA and protein expressions of c-Jun, c-
Fos, GATA-1 and NF-E2 in the nuclear and total cell extracts of Meg-01 and CHRF 
cells in a dose- and time-dependent manner (Table 7.1). These effects were 
significantly reduced when these cells were pretreated with IL-IRA (receptor 
antagonist), ActD (mRNA synthesis inhibitor) or CHX (protein synthesis inhibitor), 
indicating that the binding of IL-1 (3 to its receptors as well as specific protein 
synthesis were involved in the mechanism. The pretreatment with TPO neutralizing 
antibody had no significant effect on the stimulation of these transcription factors by 
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IL-ip, which demonstrated that the action was independent of TPO synthesized de 
novo or present in the medium. However, we could not eliminate the indirect effects 
of other cytokines such as IL-3 and IL-6 on the system. Considering the rapid and 
specific response (within 15 - 30 min) of the various transcription factors to IL-ip, 
the observed stimulations would unlikely be the secondary effect of the synthesis and 
secretion of other factors. 
Our data strongly suggested that IL-lp exerted a direct effect on MK cells and the 
mechanism might be mediated by its receptors and the up-regulation of transcription 
factors c-Jun, c-Fos, GATA-1 and NF-E2. Since primary cells and cell lines 
expressed both IL-1 (3 and receptors IL-IRI/ RII, an autocrine or paracrine effect 
might occur. The direct involvement of IL-lp in megakaryocytopoiesis and MK cell 
functions was a new concept. If proven to be physiologically significant, it would 
provide a link and possible explanations of thrombocytosis during inflammatory 
conditions. IL-1 and related proteins such as soluble IL-1 receptors, IL-lRA could be 
developed for the treatment of thrombocytopenia and inflammation-related 
conditions. In addition, the active role of IL-lp on CFU-MK formation indicated that 
it could be employed for the ex vivo expansion of MK progenitor cells for 
transplantation. 
To further understand the mechanism of IL-1 p on the MK lineage, we shall pursue to 
investigate the functional aspects of IL-1 (3 in primary MK cells and cell lines. The 
interaction of these factors with DNA in response to IL-1 (3 will be studied by the 
electrophoresis mobility shift assay. The phosphorylation assays of c-Jun and c-Fos 
will also be investigated by the binding of specific antibodies to the inactive and 
active forms of these factors. 
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mRNA level 
Transcription Meg-01 CHRF 
factors Fold increase Peak duration Fold increase Peak duration 
(mean) (mean) 
c-Jun 2.6 fold 15 min 2.9 fold 15 min 
c-Fos 2 fold 15 min 3.9 fold 15 min 
“ G A T A - 1 2 fold 60 min — 2 . 4 fold 60 min ~ 
NF-E2 5.2 fold 240 min 5.1 fold 120 min 
Protein level 
Transcription Meg-01 CHRF 
factors Fold increase Peak duration Fold increase Peak duration 
(mean) (mean) 
c-Jun 2.7 fold 30 min 3 fold 30 min 
c-Fos 2.6 fold 30 min 1.7 fold 30 min 
“ G A T A - 1 5.9 fold 60 min 11.5 fold “ 60 min ~ 
NF-E2 3 fold 240 min 12.5 fold 120 min 
Nuclear accumulation 
Transcription Meg-01 CHRF 一 factors Fold increase Peak duration Fold increase Peak duration c-Jun 9.3 fold 30 min 5.1 fold 30 min 
c-Fos 3.3 fold 一 30 min “ 4.3 fold 30 min 
GATA-1 _ 8.5 fold 60 min 2.3 fold 60 min 
NF-E2 6.5 fold 240 min 15.1 fold 120 min 
Effects on IL-ip activation 
Transcription IL-IRA TPO Ab ActD CHX 
factors 
c-Jun Inhibitory No effect Inhibitory Inhibitory 
c-Fos Inhibitory No effect Inhibitory Inhibitory 
GATA-1 Inhibitory No effect Inhibitory Inhibitory 
NF-E2 Inhibitory No effect Inhibitory Inhibitory 
Table 7.1 - A summary of the effects of IL-1 (3 on the mRNA and protein expressions 
of transcription factors in Meg-01 and CHRF cells, as well as the effects of IL-IRA, 
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